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Figure	 3.9:	 Current	 cohort	 of	 666	 patients	 sub-categorised	 via	 basic	 and	 oncological	
demographics.	 (TNM8	 section	 totals	 662	 as	 4/320	 OPC	 patients	 were	 excluded	 with	
unknown	HPV	status	therefore	could	not	be	re-staged)	





Figure	 3.11:	Mean	 values	 for	 each	dental	 domain	with	 standard	deviation	 in	 brackets	
based	on	age	decades.	One-way	ANOVA	with	95%	confidence	intervals	with	p	values	with	
those	<0.05	marked	by	an	*.	Bonferroni	correction	(p<0.003)	denoted	as	†	
Figure	 3.12:	Mean	 values	 for	 each	dental	 domain	with	 standard	deviation	 in	 brackets	
based	on	smoking	status.	One-way	ANOVA	with	95%	confidence	intervals	with	p	values	with	
those	<0.05	marked	by	an	*.	Bonferroni	correction	(p<0.003)	denoted	as	†	
Figure	 3.13:	Mean	 values	 for	 each	dental	 domain	with	 standard	deviation	 in	 brackets	
based	on	TNM7	staging.	One-way	ANOVA	with	95%	confidence	intervals	with	p	values	with	
those	<0.05	marked	by	an	*.	Bonferroni	correction	(p<0.0025)	denoted	as	†	




Figure	 3.15:	Mean	 values	 for	 each	dental	 domain	with	 standard	deviation	 in	 brackets	













on	 human	 papilloma	 virus	 (HPV)	 status	 of	 established	 oropharynx	 cancer.	 The	 lower	




with	95%	confidence	 interval.	Two-tailed	p	value	<	0.05	 is	denoted	as	 *	with	Bonferroni	
correction	denoted	as	#	
	













OPC	patients.	Unpaired	t	 test	with	95%	confidence	 interval.	Two-tailed	p	value	<	0.05	 is	
denoted	as	*	with	Bonferroni	correction	denoted	as	#		
	



























95%	 confidence	 intervals.	 p	 values	 with	 those	 <0.05	 marked	 by	 an	 *	 with	 Bonferroni	
correction	denoted	as	#	









































each	 varying	 OPC	 anatomical	 sites	 which	 is	 further	 sub-divided	 based	 on	 their	 TIL	






















Figure	 5.4:	 Shows	 the	 cohort	 divided	 based	 on	 tumour	 and	 nodal	 status.	 Laterality	 is	
present	in	brackets	as	(right/midline/left)	
	































































Figure	 6.7:	Box	 plot	 and	 comparison	 circles	 from	 TIBCO®	 Spotfire	 for	 the	 number	 of	
junctions.	 The	median	 value	 indicated	 in	 the	 related	 box	 plot	 (white	 line)	 identifies	 a	
declining	number	of	 junctions	with	more	posterior	dentition	 compared	 to	 the	 control	
group	
	
Figure	 6.8:	Box	 plot	 and	 comparison	 circles	 from	 TIBCO®	 Spotfire	 for	 the	 number	 of	
master	 segments.	 The	 median	 value	 indicated	 in	 the	 related	 box	 plot	 (white	 line)	











Figure	 7.2:	 Representative	 photomicrographs	 of	 different	 samples	which	 received	 the	
indicated	radiation.	Dose	(text	 inset)	and	 laid	out	according	 to	 the	categories	used	 for	
quantification	(rows).	 Arrow	 indicate	 patent	 vessels,	 black	 arrowheads	 indicate	















extrapolated	 fitting	 line	and	 the	dashed	 lines	 represent	 the	95%	confidence	bands.	B)	























































































































































Osteoradionecrosis	 (ORN)	 of	 the	 jaw	 remains	 one	 of	 the	 most	 feared	 late	 toxicity	
complications	 of	 head	 and	 neck	 radiotherapy	 (RT).	With	 the	 introduction	 of	 intensity	
modulated	 radiation	 therapy	 (IMRT)	many	 hypothesised	 the	 complications	 would	 be	
consigned	to	the	history	books	based	on	the	ability	to	deliver	more	focused	and	targeted	
radiation.	However,	in	contrast,	the	opposite	has	been	seen	with	ORN	still	persisting	and	









patients	 are	 divided	 by	 their	 HPV	 status	 with	 HPV	 positive	 patients	 having	 a	 vastly	
superior	 dentition.	 This	 is	 based	 on	 them	presenting	with	more	 teeth	 including	 third	
molars,	more	complex	restored	teeth	and	less	periodontal	disease.	Hence,	 though	they	
have	suffered	dental	disease	burden,	efforts	have	been	made	to	retain	their	teeth.	This	

































































































































































The	 pharynx	 commonly	 known	 as	 the	 throat	 is	 sub-divided	 into	 three	 sections.	





surface	 of	 the	 soft	 palate	 and	 uvula,	 the	 anterior	 and	 posterior	 tonsillar	 pillars,	 the	













OPC	 patients	 are	 staged	 based	 on	whether	 the	 tumour	 is	 positive	 or	 negative	 for	 the	


























































2019).	 Due	 to	 the	 limited	 vaccine	 uptake	 and	 extended	 latency	 period	 of	 HPV	 it	 is	
estimated	that	this	trend	will	continue	until	2060	(Gillison	et	al.,	2015).		
	








prevalence	of	7.7%	 for	all	 types	of	HPV	with	1.4%	being	high-risk	HPV16	 (Tam	et	al.,	
2018).	Assessment	by	gender	identified	a	much	higher	rate	in	men	with	the	prevalence	
being	9.3%	compared	 to	5.5%	 in	women	(Kreimer	et	al.,	2010).	Country	development	
status	 also	 influenced	prevalence	with	 developed	 countries	 having	 a	 7.3%	prevalence	
while	in	developing	countries	this	was	3.6%	(Kreimer	et	al.,	2010).	Even	with	oral	HPV	




Though	OPC	 and	OCC	 are	 separate	 sub-sites	 for	 HNC	 they	 have	 often	 been	 discussed	
jointly	 likely	 due	 to	 numerous	 commonalities	 such	 as	 risk	 factors	 and	 site	 proximity.	
Cancer	at	these	sites	has	a	global	footprint	with	an	estimated	400,000	incident	cases	and	
223,000	deaths	during	2008	(Ferlay	et	al.,	2010).	However,	the	incidence	of	OCC	has	been	




that	 by	 2020	 the	 incidence	 of	HPV-positive	OPC	will	 be	 greater	 than	 the	 incidence	 of	














et	 al.,	 2008).	 For	 the	 latter	3	 continents	population-based	 studies	 are	 limited	but	 also	


























The	 UK	 has	 seen	 a	 doubling	 in	 incidence	 of	 OPC	 between	 1990	 and	 2006	which	 has	
doubled	again	between	2006	and	2010	(Mehanna.	et	al.,	2016).	While	the	UK	incidence	
has	increased	by	over	100%	between	2002-2011	the	incidence	of	laryngeal	cancer	has	









































































excessive	 alcohol	 intake	persists.	 In	 contrast,	HPV	positive	OPC	patient	 profile	 is	 now	
typically	middle	 aged	 (40-59)	 (Chaturvedi	 et	 al.,	 2013;	Chaturvedi	 et	 al.,	 2011)	white,	
male	 (Chaturvedi	 et	 al.,	 2013),	 non-smoker	 (Hong	 et	 al.,	 2013),	 reporting	 little	 to	 no	













































will	 also	 be	 irradiated	 and	 therefore	 the	 treatment	 is	 non-discriminatory.	 In	 order	 to	
amplify	the	proportion	of	healthy	cells	over	tumour	cells,	 the	total	dose	is	divided	and	
delivered	into	smaller	doses	called	fractions.	This	approach	allows	healthy	cells	to	repair	
















bony	 anatomy	 and	 hand-drawn	 blocking	 towards	 specialized	 planning	 incorporating	
three-dimensional	 reconstructions	 of	 images	 and	 computer	 optimization	 algorithms	
(Bucci	et	al.,	2005).	This	advancement	accounted	for	axial	anatomy	and	complex	tissue	
contours	such	as	the	hourglass	shape	of	the	neck	and	shoulders	(Bucci	et	al.,	2005).The	














IMRT	 like	3DCRT	also	 requires	 the	use	of	 a	CT	 scan	 to	map	 the	 tumour	area	and	any	
surrounding	key	structures.	This	technique	allows	the	operator	to	control	the	number	of	
fields	 and	 intensity	 of	 each	 RT	 dose	 being	 delivered	 to	 the	 tissues	 within	 that	 field	
(IMRTCWG,	2001).	IMRT	can	be	either	fixed	beam	or	volume	modulated	arc	therapy	that	
can	 sculpt	 RT.	 Treatment	 planning	 is	 optimised	 with	 the	 assistance	 of	 a	 high-speed	
computer	 software	 (inverse	 planning	 or	 automated	 optimization),	 which	 intelligently	




advantage	 is	 that	 it	provides	the	opportunity	to	spare	 important	non-target	structures	
from	the	harmful	effects	of	radiation	(Wu	et	al.,	2000;	Xia	et	al.,	2000).	The	caveat	to	this	











many	 instances,	 the	distance	between	the	 tumour	and	critical	structures	such	as	optic	
apparatus,	 inner	 ear,	 or	 salivary	 gland	 is	 no	more	 than	 a	 few	millimetres	 (IMRTCWG,	




been	 utilized	 in	 the	 HNC	 area	 since	 its	 inception	 (IMRTCWG,	 2001).	 The	 PARSPORT	



























incidence	and	excellent	prognosis,	 in	 the	 low	 risk	group	 there	 is	 a	 concerted	effort	 to	
address	the	best	practice	in	managing	this	tumour	group	and	whether	de-escalation	of	
treatment	 is	 feasible.	 A	 multi-centre	 randomised	 study;	 PATHOS	 (UKCRN	 ID	 18645)	
 18 























































overall	 survival	 outcome	 evidently	 based	 on	 HPV	 status.	 Despite	 presentation	 with	

































102.0	 7.6	 87.1	 116.8	 106.0	 7.7	 90.8	 121.2	
Overall	
(months)	




























































preventive	 interventions	 have	 been	 employed	 the	 condition	 still	 occurs	 with	 no	
established	treatment	modality	guaranteeing	cure.			
	
In	 the	 past	 two	decades	 the	 introduction	 of	 novel	 RT	 targeted	 systems	 via	 IMRT	was	
hypothesized	to	reduce	or	even	eliminate	ORN	(Ben-David	et	al.,	2007).	Simultaneously,	
the	demographics	of	HNC	patient	has	seen	a	dramatic	change	with	rise	of	OPC	(Chaturvedi	









































Irradiated	 bone	 exposed	 through	 the	 overlying	 skin	 or	 mucosa,	




















in	 substantial	 numbers	 ranging	 from	 0.84	 –	 25.5%	 (Figure	 2.2).	 Within	 our	 own	
institution	(GSTFT)	we	have	identified	an	ORN	rate	of	5.5%	(De	Felice	et	al.,	2016).	
However,	assessing	ORN	based	on	a	generic	HNC	diagnosis	 inevitably	provides	a	wide	






























































rate	 ranging	 from	3.8	 –	11%	 (Figure	2.3).	Within	our	 institution	 the	overall	ORN	was	
10.5%	 (n=	 38/361)	 (Vinod	 Patel,	 2019)	 and	 almost	 identical	 to	 Maesschalck	 et	 al	
(Maesschalck	et	al.,	2016).	Considering	these	are	all	large	cohort	studies,	combining	them	





However,	 these	 figures	 can	 be	 deceiving	 and	 provide	 little	 overall	 value,	 particularly,	
when	trying	 to	understand	disease	pattern.	Caparotti	et	al	presented	mandibular	ORN	
rates	 in	 OPC	 incrementally,	 reporting	 3%	 at	 year	 1,	 5%	 at	 year	 3	 and	 7%	 at	 year	 5	
(Caparrotti	et	al.,	2017).	In	comparison,	based	on	these	time	points	our	OPC	cohort	had	
an	ORN	rate	of	4.7%,	9.4%	and	10.5%	respectively	(Vinod	Patel,	2019).	Hence,	the	role	of	















Author	 No	of	patients	 Primary	 RT	System	 %	ORN	
(Huang	et	al.,	2008)	
	
71	 OPC	 IMRT	 1.4	
(Avraham	Eisbruch	et	al.,	2010)	
	
69	 OPC	 IMRT	 6.0	
(Setton	et	al.,	2012)	
	
442	 OPC	 IMRT	 0.0	
(Tsai	et	al.,	2013)	 402	 OPC	 3D-CRT	(17%)		
IMRT	(83%)	
7.5	





724	 OPC	 IMRT	 4.4	
(Caparrotti	et	al.,	2017)	
	
1196	 OPC	 IMRT	 6.0	
(Wencheng	Zhang	et	al.,	2017)	 584	 OPC	 IMRT	(91%)	
IMPT	(9%)	
8.0	












1692	 OCC	 IMRT	 6.2	
(A.	Owosho	et	al.,	2017)	
	
299	 OCC	 IMRT	 4.0	













only	 to	 affect	 the	 mandible	 hence	 excluding	 the	 maxilla	 from	 the	 grading	 system.	 A	
literature	 review	 to	determine	 the	various	proposed	classification	 showed	 there	are	a	
total	of	18	classifications	(Vinod	Patel,	2016)	with	many	of	them	explicitly	focusing	only	
on	the	mandible.	Within	our	institute	the	ORN	registry	(2014	–	to	date)	has	recorded	31	
cases	 of	maxillary	 ORN	 out	 of	 a	 total	 of	 220	 cases.	 The	 inability	 to	 classify	maxillary	













no	 trauma	was	 evident	 (R.	 E.	Marx,	 1983).	 He	 suggested	 that	 the	 affected	 tissue	was	
burdened	by	hypoxia,	hypocellularity	and	hypovascularity	(3H	theory)	(R.	E.	Marx,	1983).	














lung,	 kidney	 and	 liver	 (Sylvie	 Delanian	 &	 Lefaix,	 2007).	 Histopathological	 RIF	 is	
considered	 under	 3	 main	 categories:	 pre-fibrotic	 inflammatory	 phase,	 constitutive	
fibrotic	cellular	phase	and	late	 fibro-atrophic	phase.	These	phases	are	progressive	and	
occur	over	several	years	(Sylvie	Delanian	&	Lefaix,	2007).	








A	 systematic	 review	 (Syed	Nabil	&	 Samman,	 2012)	 found	 risk	 factors	 for	ORN	 can	be	
divided	into	3	broad	categories	of	oncological,	dental	and	patient	factors.	However,	this	
















Certain	 tumour	 sub-sites	 are	 an	 integral	 risk	 factor	 for	 ORN	 simply	 based	 on	 their	








As	 indicated	 above	 some	 tumour	 sub-sites	 have	 been	 associated	 with	 ORN,	 but	 OPC	
distinguishes	 itself	 with	 a	 skewed	 leniency	 towards	 ORN.	 This	 was	 highlighted	 by	
Caparrotti	et	al drawing	attention	to	the	fact	that	patients	are	still	at	risk	of	developing	





























including	 different	 daily	 dose	 rates	 and	 treatment	 time	 identified	 conflicting	 results.	
However,	 total	 RT	 dose	 has	 been	 identified	 as	 a	 significant	 factor.	 Chang	 et	 al	 stated	




























(Sasahara	 et	 al.,	 2014)	 when	 compared	 to	 RT	 alone.	 A	 systematic	 review	 by	 Nabil	 &	
Samman	 found	 5	 studies	 supporting	 this	 view	 (Syed	 Nabil	 &	 Samman,	 2012).	 It	 is	
estimated	 that	 the	 biological	 effects	 of	 concurrent	 chemotherapy	 on	 the	 tissue	 is	









the	 main	 vulnerability	 for	 ORN.	 It	 is	 on	 this	 basis	 that	 it	 has	 become	 a	 mandatory	
requirement	 for	all	HNC	patients	due	 to	 receive	RT	 to	have	a	dental	assessment	prior	
(NICE,	2004;	RCS,	2019;	RD-UK,	2016).	Though	this	intervention	has	seen	a	reduction	in	













It	 has	 been	 long	 recommended	 that	 prior	 to	 commencing	 RT,	 patients	 should	 have	 a	
dental	 assessment.	 Guidance	 (RCS,	 2019)	 suggests	 consideration	 towards	 achieving	









Interestingly,	 a	 number	 of	 studies	 (Figure	 2.	 5)	 have	 focused	 on	 OPC	 and	 pre-RT	
extraction	leading	to	ORN	possibly	due	to	the	ironic	phenomenon.	Due	to	variant	practices	
of	dental	oncologists	 in	 the	pre-RT	phase	 it	 remains	 impossible	 to	hypothesize	on	 the	





































Post-RT	 dental	 extraction	 remains	 the	 intervention	 with	 the	 greatest	 threat	 for	 the	
development	of	ORN.	The	treatment	 induced	oral	environment	of	xerostomia,	 trismus,	
high	calorific	liquid	food	supplements	and	chronic	mucositis	all	lead	to	sub-optimal	oral	





















spontaneous	ORN	was	 elevated	 in	 the	 first	 2	 years	 and	 then	 dramatically	 fell	 to	 <1%	
subsequently	(Figure	2.6)	
	















1	 17/361	 4.7	 6/361	 1.7	 11/361	 3.0	
2	 13/313	 4.2	 4/313	 1.3	 9/313	 2.9	
3	 4/231	 1.7	 3/231	 1.3	 1/231	 0.4	
4	 2/176	 1.1	 2/176	 1.1	 0/176	 0.0	











trial	 (HOPON)	 comparing	 antibiotics	 versus	 HBOT	 did	 not	 find	 significant	 difference	





























theories	proposed	over	 the	decades.	However,	 no	 treatments	have	been	 able	 to	 claim	
guaranteed	cure.	Though	some	authors	report	high	success	rates	for	a	specific	treatment	
these	 have	 not	 been	 consistently	 repeated	 by	 others	 or	 over	 time.	 The	 inability	 to	










the	 literature	 with	 no	 one	 drug	 of	 specific	 advantage	 for	 ORN.	 The	 clinical	 protocol	
employed	involves	a	broad-spectrum	antimicrobial	in	the	acute	setting	and	if	necessary,	









Mainous	 et	 al	 proposed	 the	 use	 of	 HBOT	 (Mainous	 et	 al.,	 1973)	 but	 it	 was	 Marx’s	
endorsement	following	the	3H	theory	which	popularized	its	use	(R.	E.	Marx,	1983).	Simply	


























The	 most	 recent	 radiation	 induced	 fibrosis	 theory	 has	 led	 to	 a	 novel	 approach	 via	
pharmacological	management	(S	Delanian	&	Lefaix,	2004).	Initially	a	combination	of	two	
medications;	 pentoxifylline	 and	 tocopherol	 (S.	Delanian	 et	 al.,	 2003)	were	used	which	
were	then	supplemented	with	clodronate	(S.	Delanian	et	al.,	2011;	S.	Delanian	&	Lefaix,	
2002;	Robard	et	al.,	2014).	When	all	three	are	used	in	conjunction	they	are	often	referred	
to	as	PENTOCLO.	 In	our	 institution	 (V	Patel	et	al.,	2016b),	 this	 treatment	 strategy	has	
achieved	results	equating	that	of	Delanian	et	al	(S.	Delanian	et	al.,	2011)	notably		healing	
>	50%	of	cases.	A	recent	systematic	review	found	the	combination	of	pentoxifylline	plus	
tocopherol	with	or	without	clodronate	 to	be	effective	 for	 the	 treatment	of	mandibular	
ORN	(Martos-Fernández	et	al.,	 2018).	One	major	 limitation	 is	 their	availability	only	 in	
tablet	formation	which	impacts	on	HNC	patients	with	swallow	restriction	or	those	tube	




Pentoxifylline	 is	 a	 methylxanthine	 derivative	 licensed	 for	 use	 in	 peripheral	 vascular	
disease.	It	is	only	available	in	tablet	(modified	release)	formulation	in	the	UK.	It	has	4	main	
properties.	It	increases	erythrocyte	deformability	(Honess	et	al.,	1993),	decreases	blood	
viscosity	 (Honess	 et	 al.,	 1993),	 inhibits	 human	 dermal	 fibroblast	 proliferation	 and	








inhibition	 of	 platelet	 aggregation,	 nitric	 oxide	 production	 in	 endothelial	 cells,	 and	
superoxide	production	in	neutrophils	and	macrophages	(Packer	et	al.,	2001).		
	
Clodronate	 is	 a	 second-generation	 bisphosphonate	 that	 inhibits	 bone	 resorption	 by	
reducing	osteoclastic	activity	but	equally	act	directly	on	osteoblastic	cells	by	increasing	
formation	of	bone	and	reducing	proliferation	of	fibroblasts	(Fast	et	al.,	1978;	Fromigue	&	




The	 success	 of	 this	 regime	 validates	 the	 current	 pathophysiology	 theory	 of	 ORN.		
Historically,	it	has	seen	successful	in	reducing	radiation	induced	fibrosis	(RIF)	across	the	
body	(V	Patel	&	M	McGurk,	2017).	In	dental	cases,	its	use	has	now	extended	successfully	
from	 therapeutic	 intervention	 to	 prophylaxis	 in	 irradiated	 patients	 undergoing	 dental	










radiation	 induced	 risks.	 No	 measures	 are	 currently	 being	 taken	 to	 reduce	 or	
counterbalance	these	risks	as	the	dynamics	driving	this	disorder	are	not	well	understood.	
It	is	acknowledged	the	OPC	is	on	the	increase	and	this	group	carry	a	higher	risk	for	ORN.		
Apart	 from	 this	 little	 is	 known.	 	 Dental	 factors	 and	 RT	 doses	 are	 pivotal	 to	 ORN.	 	 A	













Secondly,	 the	 impact	 of	 RT	 on	 the	 teeth	 based	 on	 detailed	 dosing	 schedules	 needs	
exploring.	 Currently,	 pre-RT	 dental	 treatment	 planning	 takes	 place	 with	 minimal	

































































It	 is	 universally	 accepted	 that	 the	 dentition	 of	 HNC	 patients	 should	 be	 assessed	 in	
preparation	 for	radiotherapy	(RT)	(NICE,	2004).	 In	 the	UK,	guidance	 is	offered	via	 the	
Royal	College	of	Surgeons	(RCS,	2019)	and	by	Restorative	Dentistry	UK	(RD-UK,	2016).	
The	guidance	highlights	major	dental	issues	a	patient	may	face	and	offers	advice	on	both	





2013).	 This	 was	 equally	 true	 in	 the	 UK	 with	 Critchlow	 et	 al	 reporting	 extensive	






and	 a	 preference	 towards	 dental	 extraction	 rather	 than	 restoration	 of	 the	 dentition.		
Essentially,	 teeth	 do	 not	 appear	 to	 be	 a	 priority	 in	 this	 group.	 	 Traditionally	 the	HNC	
patient	 had	 a	 history	 of	 excess	 smoking	 and	 alcohol	 consumption	 and	 were	 easy	 to	
stereotype.	 The	 adverse	 effect	 of	 these	 factors	 on	 dental	 homeostasis	 is	 well	 known	
particularly	regarding	the	association	of	periodontal	disease	to	smoking	(Axelsson	et	al.,	
1998)	 and	 the	 habit	 closely	 associated	with	 oral	 cavity,	 oropharyngeal	 and	 laryngeal	
cancer	(Kojima	et	al.,	2017;	Tezal	et	al.,	2013).	Excessive	alcohol	adversely	impacts	oral	
hygiene	which	translates	into	poor	DMFT	scores	and	periodontal	disease	(Manicone	et	
al.,	 2017).	The	effects	 are	 exacerbated	when	both	habits	 are	 encountered	 in	 the	 same	





size	 and	 nodal	 involvement.	 In	 developing	 a	 dental	 oncology	 treatment	 plan	 for	 an	













pre-RT	 dental	 extractions,	 HPV	 negative	 status,	 female	 gender,	 and	 positive	 smoking	
status	were	associated	with	statistically	significant	reduced	QoL	(N.	Beech	et	al.,	2016).	
There	 is	 no	 scientific	 evidence	 to	 guide	 treatment	 and	 currently	management	 falls	 to	


















remains	 unclear	 whether	 this	 improvement	 extends	 to	 the	 modern	 cohorts	 of	 HNC	
patients.			






















The	 electronic	 out-patient	 appointments	 system	 yielded	 a	 total	 of	 1360	 new	 patient	
appointment.	 Inclusion	 criteria	 included	 biopsy	 proven	 HNC	 with	 curative	 intent	
requiring	 RT.	 A	 total	 of	 474	 patients	were	 excluded	 (non-squamous	 cell	 HNC,	 distant	
metastases,	RT	with	palliative	intent,	previous	history	of	HNC).	Edentulous	patients	were	
also	 excluded	 as	 not	 all	 these	 patients	 are	 routinely	 sent	 for	 pre-RT	 dental	 review.	
Following	exclusions,	a	total	of	886	patients	were	included	in	this	retrospective	study.		
	






























































































3.3).	 Each	 category	 showed	 high	 significance	 (p≤0.005).	 Observationally,	 there	 was	









Staging	 patients	 based	 on	 TNM7	 showed	 no	 significant	 difference	 in	 patient’s	 dental	

















HNC	 patients	were	 sub-divided	 based	 on	 standardized	 sub-site	 nomenclature	 (Figure	















	 Male	(641)	 Female	(245)	 p	value	
Teeth	Present	 20.1	(7.1)	 19.5	(7.6)	 0.2703	
Caries/Restored	 8.1	(5.1)	 8.2	(5.4)	 0.7974	
DMFT	 15.9	(7.1)	 16.5	(7.1)	 0.2609	
Horizontal	Bone	Loss	 7.5	(3.9)	 7.3	(3.7)	 0.4889	















































































































	 Current	(321)	 Ex-smokers	(336)	 Never	(229)	 p	value	
Teeth	Present	 18.1	(7.8)	 19.9	(7.1)	 22.5	(5.9)	 0.0104*	
Caries/Restored	 7.6	(5.3)	 8.3	(4.8)	 8.5	(5.2)	 0.0814	
DMFT	 17.4	(7.1)	 16.3	(6.8)	 13.8	(7.1)	 0.0000*#	
Horizontal	Bone	Loss	 8.4	(4.0)	 7.5	(3.7)	 5.9	(3.3)	 0.0000*#	













Teeth	Present	 19.0	(7.4)	 19.0	(7.9)	 19.5	(7.7)	 20.2	(7.1)	 0.2732	
Caries/Restored	 8.0	(5.3)	 8.3	(5.0)	 7.6	(5.5)	 8.2	(5.1)	 0.6549	
DMFT	 17.0	(7.2)	 17.1	(7.5)	 15.9	(7.2)	 15.8	(7.0)	 0.2231	
Horizontal	Bone	Loss	 7.3	(3.7)	 7.5	(3.8)	 7.9	(3.8)	 7.3	(3.8)	 0.4331	





	 T0	(56)	 T1	(166)	 T2	(257)	 T3	(182)	 T4(225)	 p	value	





Caries/Restoration	 8.7	(5.9)	 8.5	(5.1)	 8.9	(5.3)	 7.3	(4.9)	 7.5	(5.3)	 0.0050*#	
DMFT	 15.2	(7.0)	 16.1	(7.1)	 16.2	(7.2)	 15.9	(6.8)	 16.2	(7.4)	 0.8951	
	
Horizontal	Bone	Loss	 7.4	(4.1)	 6.7	(3.5)	 7.4	(3.8)	 8.0	(3.9)	 7.5	(3.9)	 0.0373*	

















































19.0	(6.9)	 7.9	(4.5)	 17.0	(7.3)	 7.6	(3.8)	 1.0	(1.2)	
Salivary	Gland	
(62)	
22.1	(6.7)	 8.6	(5.1)	 14.3	(7.1)	 5.4	(3.1)	 1.1	(1.2)	
Unknown	primary	
(49)	
21.1	(6.6)	 8.8	(6.1)	 15.7	(7.1)	 7.7	(4.2)	 1.4	(1.3)	
Hypopharynx	
(24)	
19.5	(7.6)	 7.8	(4.7)	 16.2	(5.6)	 8.0	(3.5)	 1.0	(1.0)	
Nasopharynx	
(39)	
23.7	(4.9)	 5.1	(4.8)	 9.0	(6.8)	 6.6	(3.6)	 2.2	(1.6)	
Oral	Cavity	
(154)	
18.3	(7.7)	 7.3	(5.5)	 16.8	(7.6)	 7.4	(3.8)	 1.3	(1.3)	
Larynx	
(192)	
17.2	(7.5)	 7.6	(4.8)	 18.3	(6.4)	 8.7	(3.7)	 1.1	(1.3)	
Oropharyngeal	
(320)	
21.1	(6.9)	 9.0	(5.1)	 15.7	(6.7)	 7.2	(3.8)	 1.4	(1.5)	
Head	&	neck	-	other	
(21)	
22.2	(5.7)	 8.3	(6.0)	 13.8	(7.0)	 5.7	(4.2)	 1.8	(1.7)	









































	 	 OPC	(n=320)	 LC	(n=	192)	 OCC	(n	=	154)	 Total	
Gender	
	 Male	 240		 157	 94	 491		
	 Female	 80		 35	 60	 175		
	
Age	
	 25-34	 2	 0	 6	 8	
	 35-44	 17	 11	 7	 35	
	 45-54	 97	 30	 39	 166		
	 55-64	 123	 62	 42	 227		
	 65-74	 66	 55	 45	 166		
	 75-84	 15	 32	 13	 60	
	 85+	 0	 2	 2	 4	
	
Smoking	Status	
	 Current	 106	 104	 49	 259		
	 Ex-smoker	 131	 76	 55	 262		
	 Never	 83	 12	 50	 145		
Staging	(TNM	7)	
	 I	 6	 40	 11	 57	
	 II	 26	 37	 9	 72	
	 III	 27	 54	 25	 106	
	 IV	 261	 61	 109	 431		
Staging	(TNM	8)	
	 I	 26	 40	 11	 77	
	 II	 150	 37	 9	 196	
	 III	 68	 54	 25	 147	








Male	 OPC	 patients	 had	 on	 average	 more	 teeth	 on	 presentation	 (p	 =	 0.0000),	 higher	
carious/restored	 teeth	 (p=0.0018),	 lower	DMFT	 (p=0.0004),	 less	HBL	 (p=0.0000)	 and	









Increasing	age	 for	all	3	sub-sites	was	 inversely	related	(Figure	3.11)	 to	 the	number	of	






A	 smoking	 habit	 was	 associated	 with	 low	 tooth	 retention.	 	 LC	 patients	 had	 the	 least	
number	of	 teeth	out	of	 the	3	 sub-sites	 for	 active	 smokers	 (p=0.0026)	and	ex-smokers	
(p=0.0011).	Those	that	never	smoked	had	the	most	teeth	(p=0.0067).	The	LC	ex-smokers’	
group,	 had	 the	 highest	 DMFT	 score	 (p=0.0054)	 and	 the	 most	 severe	 HBL	 score	
(p=0.0005).	The	non-smoking	LC	group	had	both	higher	tooth	retention	(p=0.0067)	and	























	 Sub-site	(N)	 Male	 p	value	 	 Sub-site	 Female	 p	value	
Teeth	Present	 Larynx	(157)	 17.2	(7.3)	 	
0.0000*†	
Larynx	(35)	 17.5	(8.1)	 	
0.0730	Oral	Cavity	(94)	 19.0	(7.4)	 Oral	Cavity	(60)	 17.3	(7.9)	
Oropharynx	(240)	 21.5	(6.6)	 Oropharynx	(80)	 20.1	(7.6)	
Caries/Restoration	 Larynx	(157)	 7.4	(4.6)	 	
0.0018*†	
Larynx	(35)	 8.7	(5.8)	 	
0.0646	Oral	Cavity	(94)	 7.6	(5.6)	 Oral	Cavity	(60)	 6.8	(5.1)	
Oropharynx	(240)	 9.1	(5.1)	 Oropharynx	(80)	 8.8	(5.1)	
DMFT	 Larynx	(157)	 18.2	(6.3)	 	
0.0004*†	
Larynx	(35)	 18.8	(6.4)	 	
0.2623	Oral	Cavity	(94)	 16.5	(7.8)	 Oral	Cavity	(60)	 17.2	(7.2)	






0.9002	Oral	Cavity	(94)	 7.4	(4.0)	 Oral	Cavity	(60)	 7.3	(3.5)	






0.9245	Oral	Cavity	(94)	 1.4	(1.4)	 Oral	Cavity	(60)	 1.1	(1.2)	


































































































Oral	Cavity	 	 	 	 	 	 	 	 	
















































































Oropharynx	 	 	 	 	 	 	 	 	












































































	 Sub-site	(N)	 Smoker	 p	value	 	 Sub-site	(N)	 Ex-
smoker	











	 Larynx	(12)	 23.8	(2.9)	 	
	
0.0067*	
Oral	Cavity	(49)	 16.2	(8.0)	 Oral	Cavity	(55)	 19.1	(7.0)	 Oral	Cavity	(50)	 19.7	(7.7)	












Oral	Cavity	(49)	 7.3	(5.6)	 Oral	Cavity	(55)	 8.4	(5.4)	 Oral	Cavity	(50)	 6.1	(5.3)	
Oropharynx	(106)	 9.0	(5.6)	 Oropharynx	(131)	 8.8	(4.9)	 Oropharynx	(83)	 9.3	(4.8)	









Oral	Cavity	(49)	 18.9	(6.6)	 Oral	Cavity	(55)	 17.2	(7.4)	 Oral	Cavity	(50)	 14.1	(7.9)	












Oral	Cavity	(49)	 8.1	(4.4)	 Oral	Cavity	(55)	 7.5	(3.6)	 Oral	Cavity	(50)	 6.6	(3.2)	













Oral	Cavity	(49)	 1.4	(1.2)	 Oral	Cavity	(55)	 1.1	(1.3)	 Oral	Cavity	(50)	 1.4	(1.4)	























0.0002*†	Oral	Cavity		 16.1	(6.0)	 18.0	(6.4)	 16.1	(8.3)	 19.1	(7.6)	
Oropharynx		 22.0	(4.2)	 18.5	(8.9)	 22.8	(5.4)	 21.2	(6.8)	
	 	 	 	








0.0064*	Oral	Cavity		 8.5	(5.9)	 9.4	(3.5)	 7.1	(6.2)	 7.0	(5.3)	
Oropharynx		 8.8	(5.3)	 9.3	(5.6)	 10.3	(5.5)	 8.8	(5.0)	
	 	 	 	








0.0184*	Oral	Cavity		 20.5	(5.5)	 19.4	(4.7)	 18.4	(6.9)	 15.8	(7.9)	
Oropharynx		 14.7	(5.3)	 18.7	(7.8)	 15.5	(5.3)	 15.4	(6.7)	
	 	 	 	
Horizontal	 Bone	
Loss	








0.0004*†	Oral	Cavity		 7.7	(3.4)	 9.1	(4.0)	 7.7	(3.4)	 7.1	(3.9)	
Oropharynx		 7.0	(3.4)	 8.0	(4.5)	 7.7	(3.7)	 7.0	(3.7)	
	 	 	 	
Third	 Molars	
Present	








0.3262	Oral	Cavity		 1.3	(0.9)	 1.0	(1.2)	 1.2	(1.2)	 1.4	(1.4)	






















0.3530	Oral	Cavity		 16.1	(6.0)	 18.0	(6.4)	 16.1	(8.3)	 19.1	(7.6)	
Oropharynx		 22.4	(6.5)	 21.7	(6.4)	 22.3	(5.8)	 18.8	(7.7)	
	 	 	 	








0.5726	Oral	Cavity		 8.5	(5.9)	 9.4	(3.5)	 7.1	(6.2)	 7.0	(5.3)	
Oropharynx		 10.7	(6.1)	 9.5	(4.7)	 8.8	(5.2)	 7.6	(5.3)	
	 	 	 	








0.1213	Oral	Cavity		 20.5	(5.5)	 19.4	(4.7)	 18.4	(6.9)	 15.8	(7.9)	
Oropharynx		 16.3	(6.9)	 15.6	(6.4)	 14.3	(6.2)	 16.7	(7.2)	
	 	 	 	








0.0022*†	Oral	Cavity		 7.7	(3.4)	 9.1	(4.0)	 7.7	(3.4)	 7.1	(3.9)	
Oropharynx		 6.2	(3.8)	 6.5	(3.8)	 7.6	(3.5)	 8.5	(3.5)	
	 	 	 	








0.4119	Oral	Cavity		 1.3	(0.9)	 1.0	(1.2)	 1.2	(1.2)	 1.4	(1.4)	






















Teeth	Present	 17.9	(7.1)	 18.5	(5.9)	 16.3	(8.8)	 14.8	(5.8)	 20.4	(7.7)	 0.1009	
Caries/Restoration	 6.7	(4.9)	 8.0	(5.6)	 6.4	(4.5)	 8.4	(5.4)	 7.9	(6.2)	 0.6268	
DMFT	 16.5	(7.7)	 17.5	(7.6)	 18.0	(7.2)	 21.4	(4.4)	 15.3	(7.6)	 0.2002	
Horizontal	Bone	Loss	 7.7	(3.7)	 10.6	(6.4)	 6.1	(3.7)	 9.3	(2.8)	 7.0	(3.9)	 0.0044*	









Teeth	Present	 17.5	(7.2)	 17.1	(7.5)	 16.9	(7.9)	 0.9138	
Caries/Restoration	 7.6	(4.7)	 8.1	(4.9)	 6.2	(4.7)	 0.1737	
DMFT	 18.0	(6.5)	 18.8	(6.0)	 17.4	(6.7)	 0.5129	
Horizontal	Bone	Loss	 8.4	(3.9)	 8.8	(3.2)	 8.9	(4.4)	 0.7344	










Teeth	Present	 21.9	(6.7)	 20.2	(7.0)	 20.6	(7.1)	 0.1004	
Caries/Restoration	 8.9	(5.3)	 9.1	(4.9)	 9.4	(5.4)	 0.8815	
DMFT	 14.9	(7.1)	 16.6	(6.1)	 16.7	(6.2)	 0.0712	
Horizontal	Bone	Loss	 6.9	(4.0)	 7.5	(3.5)	 6.9	(3.1)	 0.3721	























of	 teeth	consistent	with	a	 functional	dentition	 (ADHS,	2009).	 In	 the	current	 study,	 the	
mean	number	of	teeth	in	both	sexes	fell	short	of	this	threshold	at	the	time	of	their	pre-RT	
dental	assessment.	In	England,	the	mean	number	of	teeth	in	the	general	population	was	

































al	 (2013).	 In	 the	 former	 population	 of	 947	 HNC	 patients,	 59%	 were	 edentulous	
(Gaggenheimer	&	Hoffman,	1994),	14%	had	a	poor	dentition	and	18%	an	intact	dentition	
(Gaggenheimer	&	Hoffman,	1994)	compared	to	the	2013	cohort	where	only	2%	of	HNC	
patients	 were	 edentulous	 (Critchlow	 et	 al.,	 2014).	 This	 changing	 pattern	 of	 tooth	
retention	is	one	confirmed	by	ADHS	(ADHS,	2009).		
	
Another	 difference	 is	 the	 rate	 of	 dental	 caries.	 ADHS	 reported	 31%	 of	 the	 general	
population	 to	 have	 dental	 decay	 (ADHS,	 2009)	 in	 contrast	 to	 71%	 (Lockhart	&	 Clark,	
1994)	 reported	 by	 Lockhart	 &	 Clark	 and	 61%	 (Critchlow	 et	 al.,	 2014)	 reported	 by	













patients	 (Lockhart	&	Clark,	1994)	compared	 to	45%	 in	 the	general	population	 (ADHS,	
2009)	and	the	difference	probably	relates	 in	part	 to	smoking	habits.	 	The	relevance	of	
identifying	periodontal	disease	is	the	increased	risk	of	ORN	(Schuurhuis	et	al.,	2011).		If	














were	being	 retained	 in	 the	population.	Our	data	 shows	 that	patients	 impacted	by	 this	
guidance	 (age	 group	 29-52Y)	 had	 the	 highest	 number	 of	 third	 molars.	 	 The	 concern	
regarding	the	retention	of	third	molars	is	that	they	commonly	succumb	to	dental	disease	




































With	 increasing	age	(≥45-54)	 there	 is	an	emergence	of	 root	caries	 (ADHS,	2009).	This	
specific	dental	disease	is	particularly	accentuated	by	xerostomia	in	the	post	RT	phase.	In	












and	OPC	but	not	 in	LC.	 In	contrast,	 the	 latter	consistently	showed	sustained	poor	HBL	


























































presence.	This	 finding	 is	 likely	 linked	 to	 the	 increasing	number	of	OPC	patients	which	




risk	 factors	 of	 tobacco	 exposure	 and	 excessive	 alcohol	 use	 but	 rather	 related	 to	HPV.	
Hence,	 the	 lack	 of	 traditional	 risk	 factors	 means	 the	 dentition	 does	 not	 reflect	 the	
















have	 a	 differing	 dental	 profile	 possibly	 from	 prioritising	 dental	 health,	 retaining	 and	
restoring	teeth	and	differing	smoking	and	alcohol	habits.	One	pertinent	finding	in	staging	
 65 














staging	 this	cohort	 found	OPC	patients	now	have	better	dentitions	 in	 the	 lower	stages	

















the	 mandibular	 teeth	 (Bak	 et	 al.,	 2016).	 However,	 though	 various	 groups	 have	 been	
deemed	vulnerable	to	ORN	it	is	their	dental	status	which	will	compound	their	true	risk.	
The	 long-term	 presence	 of	 teeth,	 survivorship	 and	 late	 effects	 of	 radiation	 induced	
fibrosis	will	lead	to	ORN.	It	is	on	this	principle	patients	with	OPC	and	NPC	have	such	an	
elevated	risk.	The	clear	difference	in	dental	status	based	on	sub-site	is	most	evident	with	










the	 number	 reflects	more	 repaired	 teeth	which	 is	 vastly	 different	 to	 that	 reported	 by	





One	very	 interesting	 finding	 in	 this	 study	was	 the	dental	 status	of	 the	 ‘unknown	HNC	





have	 an	 unknown	HNC	 primary.	 Interestingly	when	 assessing	 their	 dental	 status	 and	
comparing	 this	 to	 the	OPC	group	of	320	patients	 the	mean	of	 each	 category	 is	 almost	
identical	with	the	standard	deviation	differences	less	than	1	tooth	apart.	This	dental	trend	
of	 such	 similarity	 essentially	 provides	 a	 blind	 test,	 which	 fits	 the	 narrative,	 that	 the	
unknown	HNC	primary	group	were	most	likely	OPC	patients.		
	




with	high	survivorship	 (Mehanna.	et	al.,	2016)	dental	oncologists	need	 to	urgently	 re-
evaluate	 dental	 management	 approach	 in	 this	 group.	 The	 balance	 of	 maintaining	 a	
















and	 OCC.	 The	 significance	 of	 an	 improved	 dentition	 on	 the	 background	 of	 post-RT	
survivorship	provides	an	insight	towards	a	rise	of	ORN	in	this	tumour	group.	Prophylactic	
molar	extractions	to	restrict	ORN	pre-RT	remain	a	controversial	practice.	Ironically,	pre-










A	 clear	 distinction	 exists	 between	 the	 dental	 status	 within	 the	 OPC	 cancer	 group	 in	
relation	to	HPV	status.	Survivorship	also	differs	with	HPV	positive	patients	having	vastly	









recognised.	 The	 study	 used	 radiographs	 alone	 to	 determine	 dental	 status	 without	
incorporating	 clinical	 examination	 data.	 Two	 main	 limitations	 have	 been	 identified.	
Firstly,	 radiographic	HBL	 reflects	historic	periodontal	disease	and	does	not	 inform	on	
 68 



















































































































status	 by	 tumour	 sub-site,	 which	 should	 be	 taken	 into	 consideration	 when	 planning	
































factors	 associated	 with	 a	 negative	 outcome	 are	 heavy	 smokers	 (>10	 pack	 years	
smoking)(Adelstein	et	al.,	2009;	Ang	et	al.,	2010;	Gillison,	Zhang,	et	al.,	2012;	Sethi	et	al.,	
2012)	 and	 advanced	nodal	 disease	 (N2b	disease	or	 above)	 (Ang	 et	 al.,	 2010).	Though	
these	factors	have	been	validated	(Ang	et	al.,	2010;	Granata	et	al.,	2012)	there	is	still	no	
widely	 accepted	 strategy	 for	 identifying	 high-risk	 HPV	 positive	 patients.	 Equally,	 no	
definitive	 criteria	 to	 identify	 HPV	 associated	 OPC	 patients	 with	 poor	 outcome	 are	
available	 either	 (Ruangritchankul	 et	 al.,	 2019).	 Recently,	 several	 studies	 utilising	
lymphocyte	subpopulation-specific	detection	 techniques	have	demonstrated	a	positive	





term	survival	 is	 a	key	 consideration	when	providing	a	pre-RT	dental	 assessment.	The	
impact	of	pre-RT	dental	extraction	on	QoL	(N.	Beech	et	al.,	2016)	and	emotional	status	of	
the	 process	 has	 predominantly	 been	 negative	 (Clough	 et	 al.,	 2018).	 With	 more	 OPC	
patients	surviving	their	disease	the	dental	oncologist	must	consider	a	more	personalised	
dental	treatment	plan.	Consequently,	it	is	important	to	identify	the	factors	that	impact	the	






























TILs	 grading	was	 completed	 in	 a	 previous	 study	 by	 Ruangritchankul	 et	 al	 as	 per	 the	






to	high-risk	HPV	 testing	by	DNA	 in-situ	hybridisation	 (INFORM	Family	 III,	Roche,	UK)	
according	to	manufacturer’s	instruction	as	previously	described	(S.	Thavaraj	et	al.,	2011).	
Only	OPC	 demonstrating	 positivity	 for	 both	 p16	 immunohistochemistry	 and	 high-risk	
HPV	DNA	by	in-situ	hybridisation	were	included	in	this	study.	TILs	were	evaluated	on	at	
least	one	representative	whole-mount	diagnostic	haemotoxylin	and	eosin	slide	from	the	
primary	 tumour	 (Ruangritchankul	 et	 al.,	 2019).	 Two	 consultant	 pathologists	
independently	 scored	TILs	according	 to	a	binary	classification	system	as	described	by	
Ward	 and	 colleagues	 (Ward	 et	 al.,	 2014).	 Lymphocytes	 present	 within	 tumour	



















dental	 status	 based	 on	 gender,	 smoking,	 anatomical	 site,	 TNM	 staging	was	 compared	











TILs	 data	 was	 patient	 matched	 to	 dental	 data	 and	 subsequently	 summarised	 using	
descriptive	statistics.	The	mean	dental	status	based	on	gender,	age,	smoking,	anatomical	
site	 and	 TNM	 staging	 was	 compared	 based	 on	 TILs-high	 and	 TILs-low	 sub-divisions.	

















the	 largest	 group	 (n=258,	 81.6%),	 however,	 following	 re-staging	 in	 accordance	 with	
TNM8,	stage	II	(n=150,	47.5%)	became	the	most	common.		
	
A	 comparison	of	dental	 health	between	HPV	positive	 and	HPV	negative	 cases	 showed	
(Figure	4.2),	the	positive	group	had	more	teeth	present	(p=0.0000),	a	higher	number	of	













significantly	 less	 teeth,	 higher	 DMFT	 and	 increasing	 HBL	 scores	 for	 all	 OPC	 patients	
(p<0.001)	a	pattern	that	mirrored	the	general	population.	When	patients	were	divided	by	
their	HPV	status	 then	 increasing	age	was	associated	with	 less	 teeth	and	higher	DMFT	
(p<0.001)	in	both	HPV	positive	and	negative	groups.	Only	HPV	positive	patients	showed	
increase	HBL	scores	with	age	(p<0.001).	Direct	comparison	of	the	dental	status	of	HPV	
positive	 vs	negative	 (Figure	4.7)	demonstrated	patients	 aged	55-64Y	had	 significantly	
more	teeth	(p=0.0001)	(23.3	vs	17.8)	a	better	DMFT	score	(15.2	vs	19.2)	and	better	HBL	




Smoking	 status	had	a	 significant	 impact	on	 teeth	present,	DMFT	and	HBL	 scores	with	
those	 that	 have	 never	 smoked	 (NS)	 having	 a	 better	 dentition	 compared	 to	 current	
smokers	(CS)	and	ex-smokers	(ES)	(Figure	4.8).	Focusing	on	HPV	positive	patients	only,	
HBL	severity	and	smoking	status	was	highly	significant	(p=0.0000)	with	CS	again	with	the	


















TMN8	 group	 is	 populated	 with	 only	 HPV	 negative	 patients	 whom	 commonly	 have	 a	
smoking	 history	 and	 therefore	 subsequently	 seen	 to	 have	 higher	 periodontal	 disease.	














The	 current	 study	 had	 a	 population	 of	 157	 HPV	 positive	 OPC	 patients.	 Sub-dividing	
patients	by	TILs	 identified	TILs-high	to	 the	most	popular	grading	(n=140,	89%).	 In	all	












Both	 DMFT	 (p=0.0072)	 and	 third	 molar	 presence	 (p=0.0177)	 were	 identified	 as	





















Gender	 Male	 239	(240)	 172	 67	
Female	 77	(80)	 43	 34	
	
Age	 25-34	 2	(2)	 2	 0	
35-44	 17	(17)	 11	 6	
45-54	 97	(97)	 71	 26	
55-64	 121	(123)	 84	 37	
65-74	 64	(66)	 38	 26	
75-84	 15	(15)	 9	 6	
	
Smoking	 Current	 104	(106)		 49	 55	
Ex-smoker	 130	(131)	 93	 37	
Never	 82	(83)	 73	 9	
	
Sub-site	 Tonsil	 166	(166)	 123	 43	
BoT	 127	(130)	 82	 45	
OP	-	other	 23	(24)	 10	 13	
	
TNM	7	 I	 6	(6)	 3	 3	
II	 25	(26)	 12	 13	
III	 27	(27)	 14	 13	
IV	 258	(261)	 186	 72	
	
TNM	8		 I	 26	 23	 3	
II	 150	 137	 13	
III	 68	 55	 13	





















HPV	Status	 	 	 	 	 	
Positive	(215)	 22.3	(6.0)	 9.5	(4.9)	 15.0	(6.4)	 6.5	(3.6)	 1.5	(1.5)	
Negative	(101)	 19.0	(7.7)	 8.1	(5.4)	 17.0	(7.0)	 8.8	(3.6)	 1.2	(1.4)	
Unknown	(4)	 12.5	(9.2)	 5.5	(1.5)	 20.0	(11.2)	 5.0	(3.1)	 0.8	(1.3)	























































HPV	+ve	 Male	(172)	 22.7	(5.6)	 9.7	(4.9)	 14.7	(6.2)	 6.4	(3.5)	 1.6	(1.5)	
Female	(43)	 20.5	(7.6)	 8.8	(5.2)	 16.3	(6.8)	 6.5	(3.8)	 1.1	(1.4)	
P	value	 0.0340*	 0.2885	 0.1392	 0.8693	 0.0489	
	
HPV	-ve	 Male	(67)	 18.4	(7.9)	 7.6	(5.5)	 17.1	(7.3)	 8.6	(3.5)	 1.3	(1.5)	
Female	(34)	 20.1	(7.2)	 9.0	(5.1)	 16.7	(6.3)	 9.1	(3.8)	 1.0	(1.3)	











Male	 HPV	+ve	(172)	 22.7	(5.6)	 9.7	(4.9)	 14.7	(6.2)	 6.4	(3.5)	 1.6	(1.5)	
HPV	–ve	(67)	 18.4	(7.9)	 7.6	(5.5)	 17.1	(7.3)	 8.6	(3.5)	 1.3	(1.5)	
P	value	 <0.0001*#	 0.0044*#	 0.0113	 0.0001*#	 0.1662	
	
Female	 HPV	+ve	(43)	 20.5	(7.6)	 8.8	(5.2)	 16.3	(6.8)	 6.5	(3.8)	 1.1	(1.4)	
HPV	–ve	(34)	 20.1	(7.2)	 9.0	(5.1)	 16.7	(6.3)	 9.1	(3.8)	 1.0	(1.3)	





Teeth	Present	 Caries/Restoration	 DMFT	 Horizontal	Bone	Loss	 Third	Molar	Present	
	 Overall	 HPV	 Overall	 HPV	 Overall	 HPV	 Overall	 HPV	 Overall	 HPV	























































































































































































































25-34	 HPV	+ve	(2)	 22.5	(5.5)	 3.5	(3.5)	 8.0	(8.0)	 1.5	(1.5)	 1.0	(0.0)	
HPV	–ve	(0)	 -	 -	 -	 -	 -	
P	value	 N/A	 N/A	 N/A	 N/A	 N/A	
	
35-44	 HPV	+ve	(11)	 25.5	(3.3)	 6.5	(4.2)	 9.0	(6.5)	 5.3	(1.7)	 1.9	(1.5)	
HPV	–ve	(6)	 25.0	(2.5)	 6.5	(2.9)	 9.3	(2.5)	 6.5	(3.1)	 1.7	(1.4)	
P	value	 0.7517	 1.0000	 0.9158	 0.3131	 0.7919	
	
45-54	 HPV	+ve	(71)	 23.5	(5.6)	 8.7	(4.6)	 13.0	(6.1)	 5.3	(3.6)	 1.6	(1.6)	
HPV	–ve	(26)	 23.3	(5.4)	 7.2	(4.3)	 11.8	(7.3)	 8.6	(3.4)	 1.5	(1.5)	
P	value	 0.8754	 0.1513	 0.4181	 0.0001*#	 0.7823	
	
55-64	 HPV	+ve	(84)	 23.3	(4.4)	 10.6	(4.8)	 15.2	(5.2)	 6.8	(3.3)	 1.6	(1.5)	
HPV	–ve	(37)	 17.8	(7.3)	 9.1	(5.2)	 19.2		(5.1)	 9.7	(3.8)	 1.0	(1.3)	
P	value	 0.0001*#	 0.1253	 0.0001*#	 0.0001*#	 0.0371	
	
65-74	 HPV	+ve	(38)	 18.7	(7.4)	 9.6	(5.6)	 18.5	(5.5)	 8.0	(3.6)	 1.1	(1.2)	
HPV	–ve	(26)	 15.8	(8.3)	 8.0	(6.8)	 20.0	(6.2)	 8.1	(3.6)	 1.1	(1.4)	
P	value	 0.1479	 0.3077	 0.3129	 0.9134	 1.0000	
	
75-84	 HPV	+ve	(9)	 14.3	(5.9)	 9.8	(3.8)	 23.1	(4.2)	 7.9	(3.8)	 0.8	(0.6)	
HPV	–ve	(6)	 15.5	(7.3)	 7.8	(5.0)	 20.3	(3.2)	 8.7	(1.2)	 1.2	(1.2)	













Teeth	Present	 19.7	(7.5)	 21.1	(7.1)	 22.9	(5.0)	 0.0060*#	
Caries/Restoration	 9.0	(5.6)	 8.8	(4.9)	 9.3	(4.8)	 0.7848	
DMFT	 17.1	(7.1)	 15.5	(6.3)	 14.1	(6.5)	 0.0085*#	
Horizontal	Bone	Loss	 8.7	(3.8)	 6.8	(3.5)	 5.8	(3.3)	 0.0000*#	











HPV	+ve	 Current	(49)	 20.8	(6.8)	 9.2	(5.0)	 16.0	(6.6)	 8.5	(4.0)	 1.1	(1.4)	
Ex-smoker	(93)	 22.3	(6.4)	 9.7	(5.0)	 15.2	(6.2)	 6.0	(3.3)	 1.4	(1.5)	
Never	(73)	 23.3	(4.6)	 9.5	(4.8)	 14.1	(6.3)	 5.7	(3.2)	 1.8	(1.5)	
P	value	 0.0777	 0.8475	 0.2496	 0.0000*#	 0.0332	
	
HPV	-ve	 Current	(55)	 19.2	(7.6)	 9.0	(6.1)	 17.7	(7.2)	 9.0	(3.7)	 1.3	(1.5)	
Ex-smoker	(37)	 18.5	(8.0)	 6.8	(4.2)	 16.2	(6.6)	 8.7	(3.5)	 1.1	(1.3)	
Never	(9)	 19.3	(6.6)	 7.8	(4.4)	 15.9	(6.7)	 7.8	(2.7)	 1.1	(1.4)	












Current	(104)	 HPV	+ve	(49)	 20.8	(6.8)	 9.2	(5.0)	 16.0	(6.6)	 8.5	(4.0)	 1.1	(1.4)	
HPV	–ve	(55)	 19.2	(7.6)	 9.0	(6.1)	 17.7	(7.2)	 9.0	(3.7)	 1.3	(1.5)	
P	value	 0.2629	 0.8563	 0.2142	 0.5094	 0.4853	
	
Ex-smoker	(130)	 HPV	+ve	(93)	 22.3	(6.4)	 9.7	(5.0)	 15.2	(6.2)	 6.0	(3.3)	 1.4	(1.5)	
HPV	–ve	(37)	 18.5	(8.0)	 6.8	(4.2)	 16.2	(6.6)	 8.7	(3.5)	 1.1	(1.3)	
P	value	 0.0053*	 0.0023*#	 0.4168	 0.0001*#	 0.2880	
	
Never	(82)	 HPV	+ve	(73)	 23.3	(4.6)	 9.5	(4.8)	 14.1	(6.3)	 5.7	(3.2)	 1.8	(1.5)	
HPV	–ve	(9)	 19.3	(6.6)	 7.8	(4.4)	 15.9	(6.7)	 7.8	(2.7)	 1.1	(1.4)	












Teeth	Present	 21.9	(6.7)	 20.2	(7.0)	 20.6	(7.1)	 0.1004	
Caries/Restoration	 8.9	(5.3)	 9.1	(4.9)	 9.4	(5.4)	 0.8815	
DMFT	 14.9	(7.1)	 16.6	(6.1)	 16.7	(6.2)	 0.0712	
Horizontal	Bone	Loss	 6.9	(4.0)	 7.5	(3.5)	 6.9	(3.1)	 0.3721	













Tonsil	(123)	 23.1	(5.8)	 9.1	(5.1)	 13.9	(6.9)	 6.1	(3.7)	 1.5	(1.5)	
BoT	(82)	 20.1	(6.2)	 9.8	(4.8)	 16.6	(5.3)	 7.2	(3.3)	 1.3	(1.5)	
OPC	(Other)	(10)	 23.2	(4.3)	 11.5	(3.7)	 16.1	(4.3)	 5.3	(3.7)	 1.6	(1.4)	




Tonsil	(43)	 18.5	(7.8)	 8.3	(5.7)	 17.7	(7.0)	 9.4	(3.7)	 1.3	(1.4)	
BoT	(45)	 19.2	(7.7)	 7.8	(4.9)	 16.5	(7.0)	 8.3	(3.7)	 1.0	(1.3)	
OPC	(Other)	(13)	 19.8	(7.1)	 8.2	(6.1)	 16.2	(6.8)	 8.0	(2.0)	 1.8	(1.7)	











Tonsil	(166)	 HPV	+ve	(123)	 23.1	(5.8)	 9.1	(5.1)	 13.9	(6.9)	 6.1	(3.7)	 1.5	(1.5)	
HPV	–ve	(43)	 18.5	(7.8)	 8.3	(5.7)	 17.7	(7.0)	 9.4	(3.7)	 1.3	(1.4)	
P	value	 <0.0001*#	 0.3919	 0.0023*#	 <0.0001*#	 0.4452	
	
BoT	(127)	 HPV	+ve	(82)	 20.1	(6.2)	 9.8	(4.8)	 16.6	(5.3)	 7.2	(3.3)	 1.3	(1.5)	
HPV	–ve	(45)	 19.2	(7.7)	 7.8	(4.9)	 16.5	(7.0)	 8.3	(3.7)	 1.0	(1.3)	
P	value	 0.4747	 0.0276	 0.9175	 0.0878	 0.2612	
	
OPC	(other)	(23)	 HPV	+ve	(10)	 23.2	(4.3)	 11.5	(3.7)	 16.1	(4.3)	 5.3	(3.7)	 1.6	(1.4)	
HPV	–ve	(13)	 19.8	(7.1)	 8.2	(6.1)	 16.2	(6.8)	 8.0	(2.0)	 1.8	(1.7)	













Teeth	Present	 22.	0	(4.2)	 18.5	(8.9)	 22.8	(5.4)	 21.2	(6.8)	 0.1378	
Caries/Restoration	 8.8	(5.3)	 9.3	(5.6)	 10.3	(5.5)	 8.8	(5.0)	 0.5242	
DMFT	 14.7	(5.3)	 18.7	(7.8)	 15.5	(5.3)	 15.4	(6.7)	 0.1171	
Horizontal	Bone	Loss	 7.0	(3.4)	 8.0	(4.5)	 7.7	(3.7)	 7.0	(3.7)	 0.5090	
















Teeth	Present	 22.4	(6.5)	 21.7	(6.4)	 22.3	(5.8)	 18.8	(7.7)	 0.0050*#	
Caries/Restoration	 10.7	(6.1)	 9.5	(4.7)	 8.8	(5.2)	 7.6	(5.3)	 0.0201*	
DMFT	 16.3	(6.9)	 15.6	(6.4)	 14.3	(6.2)	 16.7	(7.2)	 0.1786	
Horizontal	Bone	Loss	 6.2	(3.8)	 6.5	(3.8)	 7.6	(3.5)	 8.5	(3.5)	 0.0008*#	














I	-	TNM7	(6)	 22.0	(4.2)	 8.8	(5.3)	 14.7	(5.3)	 7.0	(3.4)	 1.3	(1.5)	
I	-	TNM8	(26)	 22.4	(6.5)	 10.7	(6.1)	 16.3	(6.9)	 6.2	(3.8)	 1.4	(1.3)	
P	value	 0.8873	 0.4880	 0.5997	 0.6398	 0.8698	
	
II	-	TNM7	(26)	 18.5	(8.9)	 9.3	(5.6)	 18.7	(7.8)	 8.0	(4.5)	 1.2	(1.0)	
II	-	TNM8	(150)	 21.7	(6.4)	 9.5	(4.7)	 15.6	(6.4)	 6.5	(3.8)	 1.4	(1.4)	
P	value	 0.0284	 0.8460	 0.0288	 0.0725	 0.4864	
	
III	-	TNM7	(27)	 22.8	(5.4)	 10.3	(5.5)	 15.5	(5.3)	 7.7	(3.7)	 1.3	(1.5)	
III	-	TNM8	(68)	 22.3	(5.8)	 8.8	(5.2)	 14.3	(6.2)	 7.6	(3.5)	 1.6	(1.6)	
P	value	 0.7002	 0.2153	 0.3785	 0.9019	 0.4038	
	
IV	-	TNM7	(261)	 21.2	(6.8)	 8.8	(5.0)	 15.4	(6.7)	 7.0	(3.7)	 1.4	(1.5)	
IV	-	TNM8	(72)	 18.8	(7.7)	 7.6	(5.3)	 16.7	(7.2)	 8.5	(3.5)	 1.3	(1.5)	




























20.0	(1.6)	 7.7	(3.3)	 15.7	(4.5)	 9.0	(3.6)	 2.0	(1.6)	
I/7	 HPV	–	ve	
(3)	
24.0	(5.0)	 10.0	(6.5)	 13.7	(5.8)	 5.0	(1.4)	 0.7	(0.9)	
P	value	 	 0.2574	 0.6138	 0.6616	 0.1473	 0.2873	
	 	 	 	 	 	 	
II/7	 HPV	+ve	
(12)	
20.8	(8.5)	 10.4	(6.8)	 17.6	(8.6)	 5.6	(4.8)	 1.4	(0.9)	
II/7	 HPV	–	ve	
(13)	
17.5	(8.3)	 8.6	(3.8)	 18.9	(6.6)	 10.2	(3.2)	 1.1	(1.1)	
P	value	 	 0.3364	 0.4174	 0.6740	 0.0093*	 0.4653	
	 	 	 	 	 	 	
III/7	 HPV	+ve	
(14)	
24.9	(2.0)	 10.9	(4.5)	 14.0	(4.4)	 6.0	(2.3)	 1.4	(1.6)	
III/7	 HPV	–	ve	
(13)	
20.5	(6.8)	 9.7	(6.4)	 17.2	(5.6)	 9.5	(4.0)	 1.3	(1.4)	
P	value	 	 0.0289	 0.5758	 0.1099	 0.0094*	 0.8646	
	 	 	 	 	 	 	
IV/7	 HPV	+ve	
(186)	
22.2	(6.0)	 9.4	(4.8)	 14.9	(6.3)	 6.5	(3.6)	 1.5	(1.5)	
IV/7	 HPV	–	ve	
(72)	
18.8	(7.7)	 7.6	(5.3)	 16.7	(7.2)	 8.5	(3.5)	 1.3	(1.5)	





22.2	(6.6)	 10.8	(6.0)	 16.7	(7.0)	 6.4	(4.0)	 1.3	(1.3)	
I/8	 HPV	–	ve	
(3)	
24.0	(5.0)	 10.0	(6.5)	 13.7	(5.8)	 5.0	(1.4)	 0.7	(0.9)	
P	value	 	 0.6550	 0.8311	 0.4861	 0.5592	 0.4495	
	 	 	 	 	 	 	
II/8	 HPV	+ve	
(137)	
22.1	(6.1)	 9.6	(4.7)	 15.3	(6.2)	 6.2	(3.6)	 1.4	(1.5)	
II/8	 HPV	–	ve	
(13)	
17.5	(8.3)	 8.6	(3.8)	 18.9	(6.6)	 10.2	(3.2)	 1.1	(1.1)	
P	value	 	 0.0130	 0.4583	 0.0484	 0.0002*#	 0.4835	
	 	 	 	 	 	 	
III/8	 HPV	+ve	
(55)	
22.7	(5.5)	 8.6	(4.9)	 13.6	(6.2)	 7.1	(3.2)	 1.7	(1.6)	
III/8	 HPV	–	ve	
(13)	
20.5	(6.8)	 9.7	(6.4)	 17.2	(5.6)	 9.5	(4.0)	 1.3	(1.4)	
P	value	 	 0.2198	 0.4956	 0.0598	 0.0237	 0.4104	
	 	 	 	 	 	 	
IV/8	 HPV	+ve	
(0)	
-	 -	 -	 -	 -	
IV/8	 HPV	–	ve	
(72)	
18.8	(7.7)	 7.6	(3.3)	 16.7	(7.2)	 8.5	(3.5)	 1.3	(1.5)	














HPV+ve	 I/7	(3)	 20.0	(1.6)	 7.7	(3.3)	 15.7	(4.5)	 9.0	(3.6)	 2.0	(1.6)	
	 I/8	(23)	 22.2	(6.6)	 10.8	(6.0)	 16.7	(7.0)	 6.4	(4.0)	 1.3	(1.3)	
P	value	 0.5769	 0.3944	 0.8134	 0.2964	 0.3989	
	
	 II/7	(12)	 20.8	(8.5)	 10.4	(6.8)	 17.6	(8.6)	 5.6	(4.8)	 1.4	(0.9)	
	 II/8	(137)	 22.1	(6.1)	 9.6	(4.7)	 15.3	(6.2)	 6.2	(3.6)	 1.4	(1.5)	
P	value	 0.4949	 0.5875	 0.2353	 0.5913	 1.0000	
	
	 III/7	(14)	 24.9	(2.0)	 10.9	(4.5)	 14.0	(4.4)	 6.0	(2.3)	 1.4	(1.6)	
	 III/8	(55)	 22.7	(5.5)	 8.6	(4.9)	 13.6	(6.2)	 7.1	(3.2)	 1.7	(1.6)	
P	value	 0.1475	 0.1160	 0.8213	 0.2319	 0.5332	
	
	 IV/7(186)	 22.2	(6.0)	 9.4	(4.8)	 14.9	(6.3)	 6.5	(3.6)	 1.5	(1.5)	
	 IV/8	(0)	 -	 -	 -	 -	 -	
P	value	 N/A	 N/A	 N/A	 N/A	 N/A	
	
HPV	-	ve	 I/7	(3)	 24.0	(5.0)	 10.0	(6.5)	 13.7	(5.8)	 5.0	(1.4)	 0.7	(0.9)	
	 I/8	(3)	 24.0	(5.0)	 10.0	(6.5)	 13.7	(5.8)	 5.0	(1.4)	 0.7	(0.9)	
P	value	 1.0000	 1.0000	 1.0000	 1.0000	 1.0000	
	
	 II/7	(13)	 17.5	(8.3)	 8.6	(3.8)	 18.9	(6.6)	 10.2	(3.2)	 1.1	(1.1)	
	 II/8	(13)	 17.5	(8.3)	 8.6	(3.8)	 18.9(6.6)	 10.2	(3.2)	 1.1	(1.1)	
P	value	 1.0000	 1.0000	 1.0000	 1.0000	 1.0000	
	
	 III/7	(13)	 20.5	(6.8)	 9.7	(6.4)	 17.2	(5.6)	 9.5	(4.0)	 1.3	(1.4)	
	 III/8	(13)	 20.5	(6.8)	 9.7	(6.4)	 17.2	(5.6)	 9.5	(4.0)	 1.3	(1.4)	
P	value	 1.0000	 1.0000	 1.0000	 1.0000	 1.0000	
	
	 IV/7	(72)	 18.8	(7.7)	 7.6	(5.3)	 16.7	(7.2)	 8.5	(3.5)	 1.3	(1.5)	
	 IV/8	(72)	 18.8	(7.7)	 7.6	(5.3)	 16.7	(7.2)	 8.5	(3.5)	 1.3	(1.5)	

















	 	 High	(140)	 Low	(17)	
Gender	 Male	 108	 17	
Female	 32	 0	
	










































High	(140)	 20	(7.4)	 7.6	(4.9)	 15.6	(7.2)	 7.2	(4.1)	 1.5	(1.4)	
Low	(17)	 19.0	(7.8)	 7.4	(4.9)	 16.1	(5.9)	 8.2	(4.2)	 1.2	(1.4)	








Male	(125)	 High	(108)	 20.6	(6.9)	 7.7	(4.9)	 15.0	(7.0)	 7.3	(4.3)	 1.7	(1.5)	
	 Low	(17)	 19.0	(7.8)	 7.4	(4.9)	 16.1	(5.9)	 8.2	(4.2)	 1.2	(1.4)	
p	value	 	 0.3843	 0.8149	 0.5404	 0.4226	 0.2000	
	
Female	(32)	 High	(32)	 17.9	(8.6)	 7.5	(4.8)	 17.6	(7.7)	 6.7	(3.3)	 1.1	(1.2)	
	 Low	(0)	 -	 -	 -	 -	 -	
p	value	 	 N/A	 N/A	 N/A	 N/A	 N/A	
	












18-34	(1)	 High	(1)	 24.0	(0.0)	 4.0	(0.0)	 8.0	(0.0)	 1.0	(0.0)	 0.0	(0.0)	
	 Low	(0)	 -	 -	 -	 -	 -	
p	value	 	 N/A	 N/A	 N/A	 N/A	 N/A	
	
35-44	(9)	 High	(9)	 25.1	(2.6)	 8.1	(2.5)	 10.7	(2.8)	 6.9	(4.7)	 1.4	(1.6)	
	 Low	(0)	 -	 -	 -	 -	 -	
p	value	 	 N/A	 N/A	 N/A	 N/A	 N/A	
	
45	–	54	(51)	 High	(47)	 21.2	(7.0)	 6.4	(4.1)	 13.3	(6.7)	 7.5	(4.0)	 2.0	(1.4)	
	 Low	(4)	 17.8	(6.8)	 8.3	(4.7)	 18.5	(3.9)	 11.5	(2.1)	 0.8	(0.8)	
p	value	 	 0.3548	 0.3825	 0.1346	 0.0552	 0.0992	
	
55-64	(57)	 High	(52)	 19.7	(7.1)	 8.8	(5.2)	 17.1	(7.4)	 7.3	(4.0)	 1.5	(1.4)	
	 Low	(5)	 22.6	(7.4)	 6.8	(5.6)	 11.8	(6.2)	 6.6	(4.5)	 0.4	(0.8)	
p	value	 	 0.3883	 0.4176	 0.1277	 0.7127	 0.0909	
	
65-74	(31)	 High	(23)	 16.9	(7.3)	 6.9	(5.2)	 18.0	(7.0)	 7.3	(3.6)	 0.8	(1.2)	
	 Low	(8)	 17.4	(7.9)	 7.4	(4.8)	 17.5	(5.2)	 7.6	(3.9)	 1.9	(1.6)	
p	value	 	 0.8712	 0.8131	 0.8551	 0.8437	 0.0496*	
	
75-84	(8)	 High	(8)	 17.9	(10.6)	 8.9	(6.2)	 19.0	(6.6)	 4.6	(4.5)	 1.1	(1.2)	
	 Low	(0)	 -	 -	 -	 -	 -	
p	value	 	 N/A	 N/A	 N/A	 N/A	 N/A	
	











Never	smoked	(48)	 High	(43)	 21.5	(7.1)	 7.0	(4.4)	 13.4	(6.5)	 6.7	(3.9)	 1.6	(1.5)	
	 Low	(5)	 20.4	(9.1)	 6.4	(5.5)	 13.6	(8.5)	 8.0	(4.7)	 1.2	(1.6)	
p	value	 	 0.7511	 0.7794	 0.9499	 0.4924	 0.5775	
	
Ex-smoker	(70)	 High	(63)	 19.2	(8.1)	 8.0	(5.4)	 16.8	(7.6)	 7.3	(4.2)	 1.6	(1.5)	
	 Low	(7)	 20.3	(6.9)	 8.4	(4.3)	 15.6	(3.6)	 7.4	(4.5)	 1.6	(1.5)	
p	value	 	 0.7311	 0.8507	 0.6826	 0.9528	 1.0000	
	
Current	smoker	(39)	 High	(34)	 19.6	(6.1)	 7.7	(4.4)	 16.2	(6.8)	 7.4	(4.0)	 1.3	(1.3)	
	 Low	(5)	 15.8	(6.7)	 7.0	(4.9)	 19.2	(3.6)	 9.6	(2.4)	 0.6	(0.8)	
p	value	 	 0.2063	 0.7448	 0.3437	 0.2415	 0.2519	
	
















Base	of	tongue	 High	(53)	 19.8	(7.4)	 7.3	(5.3)	 15.4	(7.3)	 7.3	(4.1)	 1.3	(1.5)	
	 Low	(10)	 19.6	(8.6)	 8.5	(4.5)	 16.3	(5.8)	 6.7	(4.4)	 0.9	(1.3)	




High	(11)	 19.8	(8.6)	 6.0	(4.7)	 14.2	(8.7)	 5.7	(3.3)	 1.8	(1.5)	
	 Low	(1)	 23.0	(0.0)	 11.0	(0.0)	 16.0	(0.0)	 14.0	(0.0)	 2.0	(0.0)	
p	value	 	 N/A	 N/A	 N/A	 N/A	 N/A	
	
Tonsil	 High	(76)	 20.1	(7.2)	 8.1	(4.6)	 15.9	(6.9)	 7.3	(4.1)	 1.6	(1.4)	
	 Low	(6)	 17.3	(6.7)	 5.0	(4.9)	 15.7	(6.7)	 9.8	(2.3)	 1.5	(1.6)	
p	value	 	 0.3599	 0.1175	 0.9456	 0.1456	 0.8679	
	






















7	-	I	(1)	 High	(1)	 17.0	(0.0)	 12.0	(0.0)	 23.0	(0.0)	 11.0	(0.0)	 2.0	(0.0)	
	 Low	(0)	 -	 -	 -	 -	 -	
p	value	 	 N/A	 N/A	 N/A	 N/A	 N/A	
	
7	-	II	(9)	 High	(6)	 19.3	(8.7)	 11.1	(5.3)	 20.0	(4.1)	 6.7	(4.8)	 1.7	(1.2)	
	 Low	(3)	 18.7	(6.8)	 7.3	(3.9)	 16.7	(3.3)	 10.3	(2.9)	 1.0	(0.8)	
p	value	 	 0.9205	 0.3127	 0.2691	 0.2794	 0.3983	
	
7	-	III	(9)	 High	(7)	 20.4	(9.2)	 9.9	(7.4)	 17.6	(6.9)	 5.9	(2.6)	 2.0	(1.2)	
	 Low	(2)	 11.0	(8.0)	 4.0	(2.0)	 20.0	(7.0)	 7.0	(4.0)	 1.0	(1.0)	
p	value	 	 0.2357	 0.3211	 0.6781	 0.6441	 0.3232	
	
7	-	IV	(138)	 High	(126)	 20.0	(7.2)	 7.3	(4.6)	 15.2	(7.3)	 7.2	(4.1)	 1.5	(1.5)	
	 Low	(12)	 20.4	(7.2)	 8.0	(5.2)	 15.3	(6.0)	 7.9	(4.3)	 1.3	(1.6)	
p	value	 	 0.8544	 0.6192	 0.9634	 0.5745	 0.6614	
	
p	value	 	 0.7668	 0.2948	 0.5152	 0.7124	 0.9346	
	
8	-	I	(17)	 High	(12)	 19.3	(9.0)	 9.4	(5.4)	 18.3	(5.9)	 6.6	(4.2)	 1.6	(1.0)	
	 Low	(5)	 15.6	(8.2)	 6.0	(3.6)	 18.0	(5.4)	 9.0	(3.7)	 1.0	(0.9)	
p	value	 	 0.4416	 0.2194	 0.9235	 0.2857	 0.2654	
	 	 	 	 	 	 	
8	-	II	(94)	 High	(88)	 19.7	(7.1)	 8.1	(5.1)	 16.4	(7.1)	 7.4	(3.8)	 1.5	(1.5)	
	 Low	(6)	 23.3	(5.3)	 8.0	(4.9)	 12.0	(6.3)	 7.7	(4.7)	 2.2	(1.7)	
p	value	 	 0.2269	 0.9630	 0.1430	 0.8541	 0.2753	
	 	 	 	 	 	 	
8	-	III	(46)	 High	(40)	 20.8	(7.4)	 6.0	(3.6)	 13.1	(7.1)	 6.8	(4.6)	 1.7	(1.5)	
	 Low	(6)	 17.5	(7.6)	 8.0	(5.5)	 18.5	(3.3)	 8.2	(3.8)	 0.3	(0.7)	
p	value	 	 0.0732	 0.2434	 0.0755	 0.4826	 0.0307*	
	 	 	 	 	 	 	













Historically,	 OPC	 was	 associated	 with	 traditional	 HNC	 risk	 factors	 such	 as	 tobacco	






When	 tailoring	 pre-RT	dental	 care	 to	 an	 individual	 patient	 it	 is	 useful	 to	 be	 aware	 of	
factors	 that	 have	 contributed	 to	 their	 dental	 disease	 as	 one	 might	 assume	 they	 will	












scores	 and	 more	 caries/restored	 teeth.	 HPV	 positive	 patients	 have	 a	 healthier,	 more	






One	 prevalent	 approach	 to	 counter	 ORN	 has	 been	 the	 radical	 practice	 of	 mass	
prophylactic	 molar	 extractions	 at	 the	 pre-RT	 assessment.	 Surprisingly,	 this	 approach	
does	not	guarantee	avoidance	of	ORN	and	ironically	can	increase	in	risk	of	this	disease	(N.	
M.	Beech	et	al.,	2017).	Also,	this	invasive	approach	creates	a	dentition	below	the	accepted	














More	 recently,	 the	 presence	 of	 TILs	within	 tumors	 has	 been	 identified	 as	 a	 powerful	




The	 use	 of	 TILs	 has	 been	 extended	 to	 HNC	 and	 particularly	 in	 OPC	 with	 studies	
consistently	 finding	 high	 TILs	 counts	 to	 have	 better	 overall	 and	 disease-free	 survival	
(Badoual	et	 al.,	 2013;	Balermpas	et	 al.,	 2016;	Dahlin	et	 al.,	 2011;	Denkert	et	 al.,	 2010;	
Ducray	 et	 al.,	 2010;	 Gooden	 et	 al.,	 2011;	 Grabenbauer	 et	 al.,	 2006;	 Keck	 et	 al.,	 2015;	
Matlung	et	al.,	2016;	Näsman	et	al.,	2009;	Nedergaard	et	al.,	2007;	Nordfors	et	al.,	2013;	






heavy	 smoking,	 and	 late	 T	 stage	 is	 extremely	 effective	 at	 identifying	 a	 group	 of	HPV-
positive	 patients	 with	 poor	 survival	 (Ward	 et	 al.,	 2014).	 The	 clinical	 value	 of	 TILs	



















The	 rise	 of	 OPC	 has	 impacted	 both	 genders	 worldwide	 in	 economically	 developed	
countries	 (Chaturvedi	 et	 al.,	 2013)	 but	 is	 more	 prevalent	 in	 the	 male	 population	
(Chaturvedi	 et	 al.,	 2013;	Chaturvedi	 et	 al.,	 2011).	There	 is	no	difference	 in	 their	basic	
dental	status	highlighting	gender	itself	does	not	influence	dentition	in	OPC.		In	the	current	
study	 males	 accounted	 for	 72%	 (172/239)	 of	 the	 HPV	 positive	 cases	 and	 had	 more	
complex	dentition.	This	inflated	population	within	OPC	identified	them	as	a	prevalent	and	
vulnerable	group.	Interestingly,	regardless	of	HPV	status,	females	had	similar	number	of	
teeth.	 However,	 it	 appears	 HPV	 negative	 patients	 are	 retaining	 these	 teeth	 on	 a	





(N.	 Beech	 et	 al.,	 2016).	 This	 creates	 a	 complex	 scenario	 to	 manage	 and	 balance	 the	



























































































59.5	 years).	 The	 impact	 of	 smoking	 is	 likely	 to	 explain	 these	 differences	 in	 dentition.	




























severity	 scores.	 There	 has	 been	 no	 proposed	 change	 to	 the	 HPV	 negative	 group	 for	













impact	 on	 third	 molar	 presence	 this	 finding	 is	 potentially	 one	 of	 significance.	 With	
evidence	that	third	molars	will	succumb	to	dental	disease,	their	position	in	the	jaws	being	






patients	 needs	 to	 be	 complimented	 by	 a	 functional	 dentition.	 The	 current	 study	
demonstrates	 that	 the	 HPV	 positive	 cohort	 have	 a	 complex	 dentition	 presenting	 new	










































































































2006).	 Prophylactic	 dental	 extraction	 continues	 to	 be	 employed,	 particularly	 in	 OPC	
(Caparrotti	et	al.,	2017)	due	to	concern	of	elevated	RT	doses	to	the	jaws	(A.	Owosho	et	al.,	





analysed	 and	 identified	 as	 risk	 factor	 (Kojima	 et	 al.,	 2017)	 for	 ORN	 in	 the	 previous	
chapters.	At	 the	pre-RT	dental	assessment,	 the	HPV	positive	group	present	with	more	








units	 produce	 poorly	 tailored	 dental	 treatment	 plans.	 Over	 treatment,	 particular	with	



















Hence,	 to	 appropriately	 treatment	plan	 the	OPC	patient	 a	better	understanding	of	 the	
doses	of	radiation	to	the	individual	dental	units	is	essential.			This	has	led	to	a	series	of	
studies	reporting	on	the	dose	to	the	dento-alveolar	segments.	Unfortunately,	preceding	
studies	 have	 shown	 significant	 limitations.	 Commonly,	 they	 have	 not	 distinguished	
between	 different	 HNC	 sub-sites,	 clustered	 tumour	 and	 nodal	 statuses	 together	 or	


















OPC	 treated	primarily	with	 IMRT	with	a	 curative	 intent.	OPC	 included	 the	base	of	 the	
tongue,	 the	 inferior	 surface	 of	 the	 soft	 palate	 and	 uvula,	 the	 anterior	 and	 posterior	
tonsillar	 pillars,	 the	 glossotonsillar	 sulci,	 the	 pharyngeal	 tonsils,	 and	 the	 lateral	 and	
posterior	 pharyngeal	 walls	 (AHNS,	 2014).	 The	 exclusion	 criteria	 included	 distant	





exclusions,	 a	 total	 of	 160	 OPC	 patients	 were	 available.	 Clinical	 information	 was	 also	
collected	 for	 each	patient,	which	 included	basic	 demographics	 (gender,	 age	 at	 time	of	




























































then	 calculated	 for	 all	 160	 patients	 and	 computed	 further	 on	 the	 basis	 of	 various	





Using	 a	 linear	 regression	 model,	 the	 average	 Dmean	 and	 Dmax	 were	 calculated	 by	
splitting	the	jaws	symmetrically	via	the	midline	to	create	4	quadrants;	lower	left	quadrant	
(LLQ),	lower	right	quadrant	(LRQ),	upper	left	quadrant	(ULQ)	and	upper	right	quadrant	









demographic	breakdown	of	 the	patients.	Males	heavily	dominated	 the	 group	 (n=	121,	










Observationally	 for	 the	 total	 cohort,	 the	average	Dmean,	Dmax	and	Dmin	of	 a	 specific	











Dmean	dental	doses	were	 seen	between	genders.	 For	 tumour	 sub-sites,	BOT	and	OPC	
(other)	 were	 seen	 to	 have	 higher	 mandibular	 average	 Dmean	 doses	 than	 tonsillar	
tumours.	In	both	tumour	and	nodal	status,	a	similar	observational	trend	was	detected	in	
the	mandible	and	maxilla.	With	increase	grading	average	Dmean	dental	doses	remained	





section	 (Supplementary	 figure	 1-8).	 Additionally,	 the	 data	 from	 this	 study	 has	 been	























	 T1	 T2	 T3	 T4	 Total	
N0	 4	(1/2/1)	 13	(5/4/4)	 6	(0/3/3)	 7	(1/0/6)	 30	(7/9/14)	
N1	 4	(2/0/2)	 5	(3/0/2)	 3	(2/0/1)	 2	(0/1/1)	 14	(7/1/6)	
N2	 22	(11/3/8)	 41	(24/3/14)	 22	(7/4/11)	 22	(4/3/15)	 107	(46/13/48)	
N3	 1	(1/0/0)	 3	(2/1/0)	 2	(1/0/1)	 3	(1/0/2)	 9	(5/1/3)	
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	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	
Left	
DMax	 60.4	 58.7	 56.2	 50.3	 46.6	 42.1	 39	 38	 38.5	 39.9	 42.4	 46.7	 51.9	 60.5	 65.1	 66.8	
	 DMean	 52.3	 49.1	 46.8	 43.1	 39.1	 34.6	 33	 32.2	 33.4	 35.5	 37.2	 40.4	 44.5	 50.6	 57.4	 62.2	
	 DMin	 41.2	 37.1	 35	 33.9	 30.3	 26.3	 26.4	 25.9	 27.3	 30	 30.7	 33.7	 36.4	 39.1	 43.9	 53.4	
	 Midline	 DMax	 61.5	 58.5	 54.9	 49.9	 44.7	 40.8	 38.5	 38.1	 37.5	 39.1	 41.6	 45.6	 50.2	 57.6	 61.6	 64.4	
	 	 DMean	 56.1	 50.7	 46.2	 43.5	 37.6	 34.6	 33.2	 31.9	 31.9	 33.6	 35.3	 38.5	 42.4	 47.8	 52.5	 57.8	
	 	 DMin	 47.2	 39.5	 35	 35.9	 29.9	 27.2	 27.5	 25.2	 25.6	 27.8	 28.2	 31.2	 33.6	 37.2	 40.3	 48	
	
Right	
DMax	 65.8	 64.5	 60.3	 54.1	 47.9	 44.4	 41.1	 39.2	 38.6	 39.7	 42.3	 46.3	 50.3	 54.9	 57.5	 59.7	
	 DMean	 61.2	 56.7	 51	 47.2	 41.9	 38.3	 36	 34.2	 33.5	 34.1	 35.8	 39.6	 43.6	 46.6	 48.7	 52.2	






DMax	 67.3	 66.9	 65.1	 58.3	 52.4	 48.4	 44.9	 43.8	
	
43.4	 43.7	 45.8	 49	 52.1	 55.8	 57.9	 58.3	
	 DMean	 63.1	 61.5	 57.1	 50.8	 45.9	 42.4	 39.3	 38	 37.7	 38.1	 39.5	 43.1	 46.8	 48.5	 49.1	 49.5	
	 DMin	 56.4	 53.1	 47.8	 44.1	 40.1	 36.7	 34.3	 33	 32.6	 32.8	 33.5	 37.1	 40.6	 40.2	 39.5	 40.1	
	 Midline	 DMax	 61.9	 61.4	 59.4	 54	 48.7	 46	 43.7	 43	 42.8	 43.2	 45.4	 48.9	 53.9	 59.3	 62.7	 63.4	
	 	 DMean	 55.3	 54.7	 51.7	 47.1	 42.5	 39.9	 38.3	 37.8	 37.6	 37.6	 38.9	 42.5	 46.8	 51.1	 54.3	 56	
	 	 DMin	 47	 46.1	 42.4	 39.7	 36.7	 34.3	 33.3	 33	 32.5	 32.3	 33	 36.2	 39.5	 42	 44.2	 46.7	
	
Left	
DMax	 59.3	 59	 56.9	 54	 51.3	 47.8	 44.6	 43.6	 43.5	 44.4	 47.5	 53.3	 59.5	 65.6	 67.5	 67.5	
	 DMean	 50.8	 50.4	 49.9	 48.1	 44.7	 41.2	 39	 38	 38.1	 40	 41.2	 45.9	 51.9	 57.6	 61.7	 63	
	 DMin	 41.3	 41	 41.3	 41.3	 37.7	 34.4	 33.5	 32.7	 32.9	 34	 35.4	 39.3	 44.3	 48.2	 52.9	 55.7	








laterality	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	




Left	 52.5	 49.2	 46.6	 42.8	 38.9	 34.5	 33.2	 32.5	 33.7	 35.6	 37.2	 40.5	 44.7	 50.7	 57.4	 61.9	
	 Midline	 55.1	 50.7	 46.6	 43.9	 37.3	 34.2	 32.9	 31.4	 31.1	 32.9	 34.8	 38.2	 42	 47.3	 52.3	 57.7	




Left	 51.6	 48.5	 47.4	 44.5	 40.2	 35	 32.4	 31	 32.5	 34.9	 36.8	 39.9	 44.1	 50.4	 57.5	 63	
	 Midline	 62.2	 50.8	 43.4	 41.6	 39.5	 37	 35.3	 35.1	 36.8	 38.4	 38.4	 40.5	 44.9	 50.9	 54.1	 58.6	







Left	 50.5	 49.5	 50	 48.6	 45.6	 42.1	 39.5	 38.5	
	
38.8	 40.4	 43.2	 48	 53.5	 59.3	 62.1	 62.8		
Midline	 56.1	 56.9	 54.8	 49.4	 45	 42.1	 39.6	 38.4	 37.7	 37	 38.3	 40.9	 44.7	 50.3	 53.1	 52.7		
Right	 63.4	 62.3	 58.5	 52	 46.9	 43	 39.5	 37.6	 36.6	 37.2	 39.4	 43.1	 45.8	 46.7	 47.2	 47.8		
Male	
(121)		
Left	 50.9	 50.7	 49.8	 48	 44.5	 40.9	 38.8	 37.9	 37.9	 38.6	 40.7	 45.4	 51.5	 57.2	 61.6	 63		
Midline	 55.1	 54.2	 51.1	 46.6	 42.1	 39.4	 38	 37.7	 37.5	 37.8	 39	 42.9	 47.3	 51.3	 54.5	 56.7		
Right	 62.9	 61.1	 56.5	 50.3	 45.4	 42.1	 39.4	 38.2	 38.2	 38.5	 39.6	 43.1	 47.2	 49.3	 50	 50.2		












laterality	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	




Left	 52.5	 49.2	 46.7	 43.2	 38.9	 34.8	 33.8	 32.6	 33.1	 34.8	 36.5	 39.7	 43.8	 49	 55.5	 60.8	
	 Midline	 53.5	 48.8	 45	 41.9	 35.5	 32.3	 31.7	 30.8	 31.2	 32.6	 33.3	 36.6	 41.3	 46.9	 51.9	 58.1	
	 Right	 57.8	 50.7	 44.5	 45.3	 38.6	 34.8	 33.6	 32.8	 32.9	 33.3	 33.4	 36.5	 38.7	 43.2	 47	 51.5	
	 Tonsil	 Left	 52.3	 49.2	 47	 43.1	 39.4	 34.4	 32.6	 32	 33.6	 35.7	 37.2	 40.6	 44.9	 51.8	 58.4	 62.8	




Left	 51.7	 47.8	 45.8	 43	 38.7	 34.4	 32.4	 31.6	 34.1	 36.9	 39.7	 42.2	 45.8	 50.6	 59.5	 63.8	
	 Midline	 58.6	 52.6	 47.4	 45.2	 39.8	 37	 34.7	 33.1	 32.5	 34.7	 37.3	 40.4	 43.6	 48.6	 53.1	 57.5	








Left	 49.7	 50.3	 49.7	 48.1	 44.3	 40.7	 39.4	 39.4	
	
39.6	 40.1	 41.5	 45.7	 50.4	 56.3	 61.5	 63.3		
Midline	 55.6	 54.4	 50.6	 45.2	 40.7	 37.3	 35.1	 34.6	 34.3	 34.3	 35.9	 40.2	 45.1	 49.8	 52.9	 54.8		
Right	 63.5	 63.9	 61.5	 57.7	 52.1	 46.6	 42.8	 40	 38.6	 38.6	 41.3	 45.9	 49.4	 51.1	 51.1	 50		
Tonsil	
(83)	
Left	 49.5	 48.8	 48.3	 46.3	 42.5	 38.8	 36.6	 35.6	 35.7	 36.7	 39	 43.6	 50.2	 56.6	 61.3	 62.8		
Right	 63.2	 61.4	 56.5	 49.8	 44.8	 41.4	 38.2	 36.7	 36.3	 36.5	 37.9	 41.4	 45.4	 47.2	 47.6	 48.2		
BoT	
(53)		
Left	 53	 52.7	 52	 50.5	 47.7	 44.5	 42	 41	 40.9	 41.8	 44.2	 49.2	 54.7	 59.5	 62.2	 63.1		
Midline	 55	 54.9	 52.8	 49	 44.4	 42.4	 41.4	 41.1	 40.8	 41	 41.8	 44.9	 48.6	 52.5	 55.7	 57.3		
Right	 62.5	 61.3	 57.3	 51.7	 47	 43.9	 42.2	 41.6	 41.9	 42.9	 44.4	 47.5	 50.2	 52.1	 53.4	 53.5		









laterality	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	




Left	 54.4	 51	 47.8	 43.9	 40	 35.9	 34.2	 32.8	 35	 37.8	 39.6	 42.7	 46.5	 51.4	 57.5	 61.6	
	 Midline	 54.1	 50.6	 48.5	 51.9	 42.6	 40.1	 38.7	 37.4	 36	 36.8	 40	 44.3	 49.3	 55.1	 59.5	 64	




Left	 53.2	 48.9	 46.7	 42.8	 38.7	 34.3	 32	 31.1	 31.5	 32.7	 34	 37.8	 42	 50.1	 56.3	 61.2	
	 Midline	 44.5	 38.1	 32.4	 29.2	 27.8	 26.7	 26.3	 25.2	 24.9	 27.2	 27.6	 29.1	 31.2	 33.8	 39.2	 46.6	




Left	 53.3	 49.7	 48	 44.4	 39.9	 35.6	 34.1	 33.3	 34	 36	 37.7	 40.5	 44.4	 49.9	 58	 63.6	
	 Midline	 64.3	 60	 55.7	 50.6	 44	 39.4	 37.6	 35.7	 36.4	 38.7	 40.4	 44.1	 48.8	 53.7	 56.6	 60.7	




Left	 45.4	 44.3	 42.6	 40	 36.6	 30.6	 30.3	 30.5	 32	 33.8	 35.6	 39.2	 44.4	 50.9	 57.9	 62	
	 Midline	 59	 51	 45.5	 44.9	 34.6	 31.4	 29.4	 29	 29.1	 29.8	 32	 35.7	 39.7	 49.6	 57.1	 62.7	




Left	 41.9	 43.5	 45.6	 44.4	 40.8	 37.4	 36.2	 35.7	
	
35.7	 36.6	 39.2	 43.9	 51.6	 58.5	 62.3	 63		
Midline	 54.1	 52.7	 47.7	 42.8	 39.2	 36.8	 35.9	 36.2	 35.9	 35.1	 36.1	 39.2	 44.7	 51.1	 54.8	 56.1		
Right	 62.5	 60	 53.7	 45.9	 41	 37.5	 35.1	 33.9	 33.6	 33.2	 34.4	 38.5	 42.2	 44.5	 45.7	 46		
T2	
(62)		
Left	 48.9	 48.6	 48.5	 46.7	 43	 39.4	 37.7	 37.1	 37.5	 38.5	 40.7	 45.6	 51	 56.8	 61.4	 63.1		
Midline	 62.5	 61.9	 59.7	 54.2	 47.9	 43.2	 39.9	 38.4	 38.1	 38.7	 40.9	 46	 50.7	 54.5	 56.2	 57.2		
Right	 62.9	 61.3	 56.6	 49.9	 45.2	 41.4	 38.6	 37.5	 37.4	 37.9	 39.5	 43.2	 47	 48.9	 49.5	 50.2		
T3	
(33)		
Left	 52.5	 51.5	 49.4	 47.1	 43.9	 39.5	 36.4	 35.2	 35.5	 36.6	 38.7	 43.7	 50.3	 57	 61.1	 62.2		
Midline	 49.2	 48.4	 45.6	 42.1	 38.9	 37.6	 36.2	 35.8	 35.1	 34.7	 35.4	 38	 40.7	 44	 47.9	 50.5		
Right	 63.6	 62.7	 60.9	 57.5	 53.6	 49.3	 45.5	 43.4	 43.1	 43.8	 45.6	 49.5	 52.2	 52.9	 51.4	 50.5		
T4	
(34)		
Left	 55.5	 54.5	 53.3	 51.8	 48.4	 45.5	 42.9	 41.8	 41.3	 42	 44.1	 48.6	 54	 58.3	 62	 63.3		
Midline	 53	 53.5	 51.3	 46.9	 42.4	 41.1	 41.7	 42.1	 42.9	 43.7	 44.3	 47.9	 52.5	 56.8	 61.1	 63.1		






laterality	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	




Left	 59	 56	 50.7	 46.6	 39.8	 35.8	 32.2	 30.6	 32.6	 35	 38	 42	 48.9	 52.7	 60.6	 65	
	 Midline	 68.2	 67	 62.3	 55.2	 45	 36.6	 33.3	 33.2	 34.1	 39.2	 44.7	 45.8	 44.9	 45.9	 51.6	 55.8	
	 Right	 64	 60.2	 55.5	 50.9	 41.4	 41	 38.2	 36.1	 36.2	 38.6	 41.3	 44.7	 48.1	 49.7	 51.5	 56.7		
N2	
(107)		
Left	 52.6	 49.3	 47	 43.7	 39.9	 35.5	 34	 33.1	 34.4	 36.6	 38.1	 40.9	 44.7	 50.4	 57	 61.4		
Midline	 53.1	 47.6	 43.5	 41.1	 34.3	 31.4	 30.6	 29.5	 29.2	 30.1	 31.6	 35	 39.6	 46.6	 52.5	 58.5		
Right	 60.7	 56	 50.5	 47	 41.8	 38.2	 36.2	 34.3	 33.5	 34.5	 36.7	 40.5	 44.2	 47.6	 49.6	 52.8		
N1	
(14)		
Left	 49.2	 46.8	 47.7	 45.3	 40.2	 33.3	 32	 31.1	 31.1	 32.5	 35.1	 39.4	 45.7	 53.4	 59.3	 63.7		
Midline	 64.9	 64.4	 60.5	 56.8	 54.6	 53.1	 50.4	 49.5	 49.5	 49.5	 53.3	 57.3	 60.7	 63.1	 64.2	 65.9		
Right	 63	 57.6	 50.8	 49	 43.5	 38.3	 36.3	 34.9	 33.8	 32.8	 33.3	 38.3	 45.9	 46.7	 49	 52.6		
N0	
(30)		
Left	 50.9	 47.5	 44.7	 39.1	 35.7	 31.4	 30	 29.4	 30.8	 32.6	 34	 38.5	 42.7	 49.6	 57.3	 63.6		
Midline	 57.9	 51.6	 46.5	 43.5	 39.6	 36.9	 35	 33.2	 33.4	 36.2	 37.5	 40.5	 44.1	 47.8	 51.1	 56		




Left	 47.3	 47.4	 46.7	 45.1	 42.5	 39.2	 36.5	 34.4	
	
33.7	 34.5	 36.8	 42	 48.9	 56.7	 61.6	 63.1		
Midline	 53.9	 53	 50.5	 45.6	 40.7	 37.4	 34.8	 33.8	 33.5	 33.5	 35.1	 38.5	 42.6	 47.3	 51	 53.5		
Right	 62.1	 60	 52.7	 42.9	 38.6	 37.1	 35.7	 34.5	 33.2	 32.5	 31.6	 31.7	 33.1	 33.7	 34	 35.2		
N1	
(14)		
Left	 42.4	 44.8	 48.7	 48.8	 46.5	 42.9	 40.6	 39.3	 39	 39.7	 41.9	 46.5	 53.6	 59.1	 62	 62.5		
Midline	 63.8	 64.1	 61.4	 56.5	 52.3	 50.2	 49.5	 48.9	 47.9	 47.9	 49.2	 55.1	 60.2	 63.3	 65.4	 65.8		
Right	 63.9	 62.5	 57.3	 52.5	 47.6	 42	 39.3	 39.5	 41.6	 41.9	 40.5	 44	 46.9	 48.8	 49.2	 50.8		
N2	
(107)		
Left	 52.4	 51.4	 50.4	 48.6	 44.9	 41.5	 39.5	 38.9	 39.2	 40.2	 42.4	 47	 52.6	 57.7	 61.6	 62.9		
Midline	 54.6	 54.1	 50.6	 46.6	 42.5	 40.6	 39.8	 39.8	 39.5	 39.5	 40.2	 43.5	 48	 52.3	 55.5	 56.9		
Right	 63.1	 61.6	 57.6	 51.5	 46.7	 43	 39.8	 38.2	 37.7	 38.1	 40.2	 44.5	 48.5	 50.5	 51.2	 51.4		
N3	
(9)		
Left	 59.9	 60.1	 58.1	 53.8	 48.4	 42.4	 38.8	 38	 38.1	 39	 41	 46	 52.1	 58.1	 62.7	 64		
Midline	 68.8	 67.8	 66.4	 57.3	 49.1	 42.8	 38.7	 37.8	 38.7	 40.8	 45.9	 54.6	 57	 58.2	 56.1	 57.9		
























Dmean	dose	whereas	males	had	 the	maximum	Dmean	dose.	Box	plot	 analysis	 (Figure	






















































































ULQ	Dmax	 0.3842	 0.0060	 Intercept	 <0.0001♯	
ULQ	Dmean	 0.2797	 0.0169	 Intercept	 <0.0001♯	
URQ	Dmax	 0.1848	 0.0305	 Intercept	 <0.0001♯	




































Male	 24.48	 47.64	 47.01	 65.07	
Female	 21.93	 48.60	 46.22	 58.98	
	
Midline	 24.58	 45.61	 51.13	 54.35	
Left	 37.47	 49.27	 49.84	 64.86	
Right	 21.93	 45.21	 43.91	 65.07	
	
OP	-	other	 24.58	 45.84	 45.76	 61.85	
Tonsil	 21.93	 46.12	 45.01	 61.24	
BoT	 29.08	 50.11	 50.02	 65.07	
	
T1	 21.93	 45.06	 43.52	 58.98	
T2	 24.09	 46.78	 46.33	 61.24	
T3	 24.48	 48.42	 46.72	 61.56	
T4	 27.95	 50.88	 50.93	 65.07	
	
N0	 21.93	 43.70	 42.31	 55.96	
N1	 28.92	 48.31	 48.45	 60.93	
N2	 24.48	 48.18	 47.78	 65.07	




Male	 23.67	 47.47	 46.78	 65.92	
Female	 26.11	 48.44	 48.27	 60.58	
	
Midline	 23.67	 48.68	 45.91	 55.84	
Left	 26.11	 45.80	 45.27	 63.26	
Right	 35.90	 49.52	 49.68	 65.92	
	
OP	-	other	 23.67	 47.13	 46.41	 56.68	
Tonsil	 26.11	 47.23	 46.37	 62.30	
BoT	 28.84	 48.78	 48.65	 65.92	
	
T1	 31.49	 42.87	 43.60	 53.13	
T2	 26.11	 48.78	 47.66	 58.30	
T3	 23.67	 47.32	 46.94	 62.82	
T4	 28.84	 50.55	 49.73	 65.92	
	
N0	 23.67	 45.14	 43.50	 53.80	
N1	 31.49	 45.80	 48.19	 62.82	
N2	 28.84	 48.58	 47.84	 65.92	




















Male	 3.178	 44.75	 42.89	 64.09	
Female	 24.84	 45.93	 44.85	 57.04	
	
Midline	 5.20	 44.42	 42.48	 59.58	
Left	 27.95	 45.93	 45.06	 61.52	
Right	 3.18	 43.61	 41.66	 64.09	
	
OP	-	other	 26.18	 43.99	 44.04	 61.52	
Tonsil	 20.31	 45.43	 43.86	 59.21	
BoT	 3.18	 44.63	 42.31	 64.09	
	
T1	 3.18	 44.33	 41.86	 56.68	
T2	 20.31	 44.94	 43.41	 59.58	
T3	 5.20	 44.75	 42.25	 55.88	
T4	 27.95	 45.60	 45.54	 64.09	
	
N0	 20.31	 41.88	 40.97	 59.58	
N1	 23.03	 47.11	 45.45	 57.94	
N2	 3.178	 45.23	 43.53	 64.09	




Male	 2.903	 44.60	 43.03	 62.61	
Female	 21.55	 46.02	 44.96	 57.54	
	
Midline	 2.90	 46.55	 43.23	 60.25	
Left	 19.02	 41.67	 41.10	 55.45	
Right	 29.38	 47.66	 46.49	 62.61	
	
OP	-	other	 27.68	 46.21	 44.52	 60.25	
Tonsil	 19.02	 45.53	 43.95	 57.49	
BoT	 2.90	 42.76	 42.35	 62.61	
	
T1	 27.88	 42.94	 41.68	 53.04	
T2	 21.55	 46.04	 45.00	 60.25	
T3	 2.90	 42.36	 41.79	 60.41	
T4	 32.16	 42.90	 43.70	 62.61	
	
N0	 21.55	 40.89	 40.42	 60.25	
N1	 32.30	 44.76	 45.76	 60.41	
N2	 2.90	 45.47	 43.75	 62.61	




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Radiation	dose	 is	 considered	 the	most	 significant	predictor	 for	ORN	 (Ben-David	et	 al.,	
2007)	and	studies	routinely	report	a	relationship	of	maximum	RT	doses	>60–75Gy	(Ben-
David	et	al.,	2007;	Chen	et	al.,	2016;	Glanzmann	&	Grätz,	1995;	A.	Owosho	et	al.,	2017;	J.	J.	














RT	dose	and	chronic	hypoxia	of	 the	mandibular	bone	 (Poort	et	al.,	2017).	 	The	higher	
radiation	dose	leads	to	increased	amount	of	fibrosis,	resorption,	lacunae	and	woven	bone	
while	bone-remodelling	 rates	decrease	 (Poort	 et	 al.,	 2017).	 In	 the	 current	OPC	 cohort	
using	either	patient	or	tumour	demographics	the	median	in	all	quadrants	had	a	Dmean	of	
>	40Gy	(Figure	5.12-5.17).	Using	the	40Gy	threshold,	the	present	investigation	shows	that	
in	 OPC	 patients	 all	 quadrants	 of	 the	mouth	 are	 potentially	 at	 risk	 of	 developing	 ORN	
irrespective	of	additional	adverse	demographics	factors.			
	
The	 tissue	 impact	 of	 RT	 >40Gy	 is	 not	 solely	 on	 the	 bone	 but	 also	 the	 teeth.	 In	 doses	
exceeding	30-35Gy	 the	dental	pulp	has	 less	sensitivity	 (Garg	et	al.,	2015).	Those	 teeth	




even	with	multiple	 teeth	 involved.	 	 In	 the	current	 study,	RT	dental	doses	>30Gy	were	










Doses	outlined	 in	Figure	5.6	and	supplementary	 figures	1-8	highlights	 the	need	 to	 re-
evaluate	the	practice	of	prophylactic	molar	extraction	of	sound	teeth,	particularly	on	the	




above	 40Gy.	 These	 reported	 doses	may	 explain	why	 pre-RT	 dental	 extractions	 is	 not	




5.6).	 	 This	 finding	 is	 consistent	with	 the	doses	 reported	by	Rosenthal	 et	 al	 showing	 a	
significantly	 larger	 part	 of	 the	 anterior	mandible	may	 be	 subjected	 to	 a	 ‘‘beam	 path”	











RT	 doses	 in	 established	 ORN	 in	 OPC	 has	 not	 followed	 the	 accepted	 trend	 of	 >	 60Gy.	
Owosho	AA	et	al	showed	a	Dmax	range	from	44.3-80.9	Gy	(average,	69.6Gy)	and	a	Dmean	
28.2-74.6	 Gy	 (average,	 57.4	 Gy)	 (A.	 Owosho	 et	 al.,	 2017).	 However,	 it	 needs	 to	 be	
recognised	that	the	state	of	the	dentition	also	varies	(Vinod.	Patel	et	al.,	2020;	V.	Patel	et	
al.,	2020)	 independent	of	 the	radiation	dose.	The	OPC	group,	and	particularly	 the	HPV	
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Gender	was	explored	 for	dental	dose	difference,	however,	when	 compared,	 a	minimal	
difference	of	2-4	Gy	was	observed	(Figure	5.12-5.13).	Clinically	this	seems	negligible	and	
may	 lead	 to	disregarding	 this	 as	 a	 factor.	Though	 their	RT	doses	may	be	 similar	 their	
dentitions	 differ,	 and	 both	 need	 to	 be	 considered	 jointly.	 Results	 presented	 in	 the	
preceding	 2	 chapters	 discovered	 that	 at	 the	 pre-RT	 dental	 assessment	 phase,	 male	
patients	are	reported	to	have	both	more	teeth	and	of	complex	status	compared	to	females	







ORN	 is	 heavily	 weighted	 towards	 males	 this	 imbalance	 is	 likely	 to	 reflect	 the	 higher	
incidence	of	HNC	in	this	population	including	in	OPC.	However,	in	this	study,	males	were	
consistently	 identified	 as	 having	 a	 higher	 maximum	 Dmean	 doses.	 Taking	 this	 into	
consideration	plus	male	OPC	patients	to	have	a	complex	dentition	and	being	a	populous	
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Established	 tumours	 that	 can	 be	 consigned	 to	 a	 side	 are	 expected	 to	 have	 higher	
individual	RT	doses	at	the	tooth	level	compared	to	the	contralateral	aspect.	However,	on	
a	wider	perspective	this	finding	can	be	argued	as	misleading.	Considering	RT	doses	at	the	






















with	 the	 current	 study	 able	 to	 provide	 supplementary	 findings	 to	 explain	 this	
phenomenon.	 Increasing	 tumour	 size	 identified	 increasing	median	Dmean	dose	 in	 the	
mandible	as	expected	with	larger	tumours	having	larger	CTV	and	encompassing	safety	
margin	(planned	target	volume).	In	such	a	constricted	environment	the	involvement	of	
adjacent	 structures	 is	 often	 inevitable	 such	 as	 the	 jaws	 and	 the	 dentition.	 While	
attempting	 to	avoid	vital	 structures	such	as	 the	parotid	gland	and	 the	spinal	cord	 this	
therefore	requires	delivery	through	the	mandible,	which	is	often	unavoidable	particularly	















with	 advanced	 classification	 (N2	 or	 N3)	 nodal	 disease	 (Ang	 et	 al.,	 2010).	 The	




with	 safety	margins	 are	 inadvertently	 likely	 to	 involve	 the	 jaws.	 In	 lateralized	 T1-T2	



















































tonsil,	 26	 BoT)	 patients	 (Bak	 et	 al.,	 2016).	 They	 concluded	 that	 dose	 distribution	 is	
dependent	on	tumour	site	but	also	the	geographic	proximity	of	the	cancer	to	the	dentition.	
Compared	to	our	data	(Supplementary	Figure	10)	the	doses	reported	by	Bak	SY	et	al	were	











































Dental	 dosimetry	 in	 OPC	 can	 vary	 based	 on	 tumour	 laterality	 as	 well	 as	 series	 of	



















Considering	 RT	 doses,	 firstly,	 protocols	 for	 tumour	 volumes	 and	 contours	may	 differ	
between	clinical	units.	Secondly,	direction	of	tumour	growth	may	also	vary	for	the	same	
tumour	grading.	An	obvious	example	would	be	a	T4	tumour,	which	extends	superiorly	






















































































With	 the	 most	 recent	 pathophysiology	 of	 RIF	 proposed	 by	 Delanian	 et	 al	 the	 loss	 of	
vascularity	in	the	long	term	leads	to	atrophy	and	in	the	case	of	the	jaws,	ORN	(S	Delanian	
&	Lefaix,	2004).	RIF	leading	to	atrophy	have	been	shown	in	breast,	skin,	liver	and	kidney	
and	 also	 in	 the	 jaws	 (V.	 Patel	 &	 M.	 McGurk,	 2017).	 However,	 in	 the	 IMRT	 era	 the	
hypothesis	proposed	was	this	will	be	reduced	considering	the	novel	technology	is	better	



























times.	 Standardized	 data	 acquisition	 procedures	 are	 necessary	 for	 providing	 reliable	
clinical	 assessments	 of	 irradiation-induced	 side	 effects	 and	 facilitate	 identifying	





































based	on	 the	 emission	of	 green	 light	 (Wavelength:	 520	nm)	directed	 to	 the	 examined	
tissue	to	benefit	from	the	natural	contrast	mechanism	of	haemoglobin	inside	red	blood	
cells	(RBC).	Green	light	is	well	absorbed	by	haemoglobin,	but	the	surrounding	tissues	(e.g.	





–	 Storz®),	 filtered	 by	 a	 520/20	 nm	 band	 pass	 filter	 producing	 an	 incoherent	
monochromatic	(green)	light,	relayed	to	the	tissues	via	a	dedicated	fibre-optic	cable	(Karl	
Storz®	-	495L)	and	the	endoscope’s	conventional	segregated	illumination	channel	(Karl	
Storz®	 -	 Hopkins	 II	 26157RTA).	 As	 the	 green	 backscattered	 light	 is	 absorbed	 by	
haemaglobin	pigments,	the	consequent	images	show	low	intensity	RBCs	moving	through	
the	 higher	 intensity	 background	 image.	 Endoscope	 eyepiece	 images	 are	 relayed	 via	 a	
magnification	 system	(Thorlabs®	SM1NR05)	 to	a	high	 resolution	 (2040	x	2040	pixels)	
analogue	monochrome	charge	coupled	detector	(Basler®	ACA	4060).	A	subsequent	8	bit	
analogue	 to	 digital	 converter	 (ADC)	 digitizes	 the	 signal	 (following	 a	 binary	 system),	
allowing	each	pixel	one	of	28	(256)	different	greyscale	values.	This	output	 is	 sent	 to	a	













mucosa	 of	 the	 edentulous	 site	 following	 the	 same	 image	 protocol	 (e.g.	 magnification,	



















artefacts	 from	 the	 FOV.	 In	 this	 instance,	 image	 selection	 and	 artefacts	 removal	 were	
performed	by	a	single	clinical	examiner.	Subsequently,	all	results	were	converted	to	the	
same	 FOV	 (1	mm2),	 allowing	 a	 standardized	 comparison	 between	 images.	 	 Figure	 6.2	
shows	the	image	timeline	from	retrieval	to	analysis.	
	
Additionally,	 TIBCO®	 Spotfire,	 a	 visual	 analytic	 software,	 highlighted	 important	
discriminatory	parameters	in	the	analysis.	These	parameters	were	reduced	to	4	in	order	



























Number	of	pieces	 Total	 number	 of	 segments,	 master	 segments,	
junctions,		master	junctions.	
	
























































outlines	 further	 presenting	 demographics.	 In	 the	 control	 group,	 8	 healthy	 and	 non-






lower	 for	 the	maxilla	with	average	Dmean	for	 the	second	molar,	second	premolar	and	
lateral	incisor	being	53.6	±	9.7Gy,	45.6	±	10.8Gy,	36.2	±	7.9Gy	respectively.		
	
Overall,	 the	 microvascular	 parameters	 within	 the	 RT	 group	 were	 decreased	 when	
compared	 to	 the	 control	 group,	with	17	parameters	 identified	as	 significant.	 	 	 p	 value	
ranged	from	0.001	in	the	total	branch	length	and	0.054	in	the	number	of	master	junctions.	






assessed	 independently.	 Similar	vascularization	patterns	were	 found	 in	 the	upper	and	
 145 
lower	jaws.	In	the	upper	jaw	there	was	a	decrease	in	the	vascular	area	of	43.2	%	in	the	







comparing	 the	 ipsilateral	 side	with	 the	 contralateral	 side.	To	 eliminate	dilution	of	 the	
results	by	including	all	gingival	regions	receiving	different	doses	of	RT,	specifically	the	
second	molar	region	was	compared	from	both	sides.	As	the	RT	dose	map	identified	this	
area	 receives	 the	highest	 dose.	Again,	 according	 to	 all	 CAA	parameters	 there	were	no	
significant	differences	(p	value	=	0.179	-	0.904).		
	
Figure	6.5	shows	the	decreasing	value	of	each	category	as	 the	 time	 from	RT	 increases	







fronts	 in	 the	 RT	 group	 versus	 the	 control	 group.	 Using	 these	 parameters	 comparing	
individual	dental	sites	again	RT	sites	had	a	reduced	number	in	comparison	to	the	control	
group	(p	£	0.05).	Data	is	summarised	in	figure	6.6.	Using	box	plot	analysis	(Figure	6.7-















1	 49	 7	 Nil	 Nil	 Never	 Tonsil	 Right	 Concomitant	 Cisplatin	 2	
2	 63	 6	 Hyperlipidaemia	 Simvastatin	 Never	 Tonsil	 Left	 Concomitant	 Cisplatin	 2	
3	 34	 6	 Nil	 Nil	 Never	 Tonsil	 Right	 Induction	 &	
concomitant	
Cisplatin	&	5FU	 4	
4	 59	 5	 Nil	 Sildenafil	 Never	 Tonsil	 Left	 Concomitant	 Cisplatin	 2	
5	 52	 5	 Nil	 Nil	 Ex-smoker*	 Tonsil	 Right	 Induction	 &	
concomitant	
Cisplatin	&	5FU	 4	












Ex-smoker*	 Tonsil	 Right	 Induction	 &	
concomitant	
Cisplatin	&	5FU	 4	




Never	 Tonsil	 Right	 Induction	 &	
concomitant	
Cisplatin	&	5FU	 4	






Ex-smoker*	 Tonsil	 Right	 Concomitant	 Cisplatin	 2	
10	 67	 4	 Hypertension	 Indapamide	 Ex-smoker*	 Tonsil	 Right	 Induction	 &	
concomitant	
Cisplatin	&	5FU	 4	


























Patient		 		 LL7	 LL5	 LL2	 LR2	 LR5	 LR7	 UL7	 UL5	 UL2	 UR2	 UR5	 UR7	
1	 Dmax	 65.5	 55	 43.3	 43.8	 46.4	 65.7	 57.7	 45.1	 38.1	 44.7	 48.9	 61.3	
		 Dmean	 57	 49.3	 39.8	 40.1	 40.6	 53	 46.7	 26.9	 23.8	 38	 43.1	 45.2	
2	 Dmax	 67.2	 68.3	 43.1	 48.6	 63.6	 59.4	 66.2	 59.7	 46.7	 49.6	 63.3	 65.2	
		 Dmean	 64.8	 63.8	 36.3	 41	 55.6	 46.8	 62.7	 51.9	 42.4	 43.5	 59.7	 56.7	
3	 Dmax	 60.9	 60.7	 50.7	 46.2	 66.7	 67.4	 61.7	 57.7	 49.8	 46.8	 64.4	 67.9	
		 Dmean	 52.5	 53.3	 44.4	 40	 62.2	 64	 49.8	 51.9	 44.9	 41.8	 57	 64.8	
4	 Dmax	 67.6	 60.8	 37.4	 33.8	 58	 68	 67.3	 51.5	 44.7	 41.3	 51.9	 64.1	
		 Dmean	 62.8	 55	 33.4	 31.8	 51.6	 62.6	 58.7	 46.3	 40.4	 35.7	 44.9	 55.8	
5	 Dmax	 68.9	 63.9	 51.5	 50	 60.3	 66.9	 66.2	 44.7	 40.4	 40.8	 48.3	 64.4	
		 Dmean	 59.8	 58.7	 39.5	 40.5	 53.6	 63.3	 57.1	 41.5	 36.5	 37.5	 42.2	 55.2	
6	 Dmax	 68.2	 64.7	 49.8	 49.7	 59.2	 65	 67.9	 60.8	 45.3	 47.9	 52.3	 62.1	
		 Dmean	 63.4	 59.7	 46.1	 42.2	 52.9	 53.9	 63.8	 52	 38.2	 43.3	 48.8	 55.1	
7	 Dmax	 58.4	 48.4	 43.1	 47.3	 59.1	 66.1	 60.8	 47.1	 39.3	 48	 55	 66.3	
		 Dmean	 48.6	 41.7	 37	 43.4	 50.9	 62.2	 47.7	 42.9	 37.3	 43	 52.4	 63	
8	 Dmax	 56.6	 51.8	 40.9	 42.7	 59.8	 66.9	 55	 45.8	 34.7	 37	 57	 68.5	
		 Dmean	 41.8	 43.9	 32.5	 37.8	 53.9	 60	 44	 42.7	 32.3	 30	 48.6	 61.6	
9	 Dmax	 59.5	 54.1	 36.2	 37.4	 51.7	 68.8	 65.1	 58.8	 42.2	 46	 59.5	 67.4	
		 Dmean	 47.6	 46	 30.6	 30.7	 41	 63.8	 46.8	 50.5	 38.1	 42.8	 51.5	 63.1	
10	 Dmax	 63.9	 57.9	 49.3	 49.8	 64.4	 67.9	 65.3	 57.9	 43.3	 50.4	 60.3	 66.1	
		 Dmean	 53	 51.1	 42.9	 46.5	 57.6	 64.9	 58.8	 52.9	 38.2	 44.9	 54.8	 62.7	
11	 Dmax	 64.3	 42.7	 42.4	 42.5	 44.1	 62.3	 56.6	 33.4	 34.6	 34.5	 32.9	 53.7	
		 Dmean	 52	 36.1	 35.3	 36.4	 38.4	 52.3	 42.5	 27.1	 26.9	 24.7	 24.6	 36.4	
12	 Dmax	 63.8	 53.2	 43.9	 50.9	 63.5	 63.8	 63.8	 59	 44.9	 47.1	 65.1	 67.9	
		 Dmean	 49.3	 49.9	 39	 47.8	 58.1	 60.3	 60.3	 56.1	 41.4	 39.8	 59.2	 63.2	
13	 Dmax	 59.9	 40.4	 35.5	 43.8	 65.2	 66.6	 44.4	 33.3	 24.7	 32	 58.1	 65.9	











































































































































Novel	 IMRT	 though	 targeted,	 exposes	 a	 larger	 amount	 of	 non-targeted	 tissues	 to	





over	 time	(Barnett	 et	 al.,	 2009;	 Jellema	 et	 al.,	 2007;	 Langendijk	 et	 al.,	 2008).	 The	
development	 of	 irradiated	 tissue	 changes	 long	 term	 is	 often	 referred	 to	 as	 radiation	
induced	 fibrosis	 (RIF)	 and	 subsequent	 tissue	 death	 as	 radiation	 induced	 atrophy	 (S	
Delanian	&	Lefaix,	2004).	For	the	latter,	ORN	is	a	common	example	of	this.	The	concept	of	






M	McGurk,	2017)	with	RT-related	 factors	playing	a	key	role.	These	 factors	 include	the	









in	 the	 soft	 tissues	 post	 RT	 leading	 to	 late	 effects	 can	 be	 assessed	 in	multiple	 formats	
(clinical,	imagery,	histopathology)	(S	Delanian	&	Lefaix,	2004).	Clinically,	four	stages	are	
described;	 pre-fibrosis,	 established	 fibrosis,	 late	 fibrosis,	 and	 atrophy	 (necrosis)	 (S	
Delanian	&	Lefaix,	2004).	In	contrast,	histopathological	changes	commence	immediately	








Delanian	 &	 Lefaix,	 2004).	 As	 for	 imagery,	 various	 methods	 have	 been	 employed	 to	
quantify	microstructural,	and	metabolic	data	via	positron	emission	tomography	(PET),	
single	photon	emission	tomography	(SPECT),	magnetic	resonance	(MR)	imaging	and	MR	
spectroscopy.	 However,	 these	 investigations	 lack	 the	 ability	 to	 provide	 small	 volume	
microvessel	differences	and	discrepancies	which	are	vital	 to	considering	post-RT	hard	
and	 soft	 tissue	 changes	 for	 the	 various	 anatomical	 structures	 of	 the	 oral	 cavity.	 Dose	
dependent	 mandibular	 bone	 vascular	 alterations	 related	 to	 chemo-RT	 has	 been	















posterior.	 However,	 a	 clear	 significant	 difference	 was	 identified	 in	 the	 status	 of	 the	
microvasculature	as	it	migrated	posteriorly	in	the	RT	group	(Figure	6.6-6.10).	The	one	
substantial	 factor	 changing	was	 the	RT	dose	which	 increased	with	 the	more	posterior	







these	 regions	with	 the	 normal	 control	 group.	 Though	 vascular	 depletion	was	 evident	
 155 
minimal	further	information	about	the	microvasculature	could	be	determined	as	gingival	
capillary	 loops	 are	 observed	 from	 an	 axial	 perspective,	 hence	 its	 shape	 resemble	
“commas”	 and	 “dots”	 (Alessandro	 et	 al.,	 2009)	 which	 limits	 further	 morphological	
assessment.		
	
Though	 the	 study	 was	 unable	 to	 determine	 an	 exact	 RT	 threshold	 dose	 for	
microvasculature	changes	worryingly	this	was	evident	even	at	low	doses	and	raises	the	
debate	 of	 whether	 the	 traditional	 40Gy	 benchmark	 of	 irreversible	 RT	 changes	 is	 still	
applicable.	The	average	Dmean	 for	 the	anterior	maxilla	was	36.2Gy.	Even	at	 this	dose	
significant	changes	in	the	microvasculature	anatomy	were	noted.	This	 lower	threshold	
for	 the	 microvasculature	 depletion	 should	 not	 be	 a	 surprise	 considering	 RT	 induced	
mucositis	typically	begins	at	doses	around	15-20	Gy	(Scully	et	al.,	2004)	affecting	80%	of	
patients	 (Trotti	 et	 al.,	 2003).	 At	 30	 Gy	 ulcerative	 mucositis	 occurs	 and	 subsequently	
evolves	 from	 asymptomatic	 focal	 hyperemia	 and	 edema	 to	 symptomatic	 patchy,	 then	










changes	 in	 vessel	 size	 and	 diameter,	 vessel	 architecture,	 and	 average	 blood	 velocity	





with	 the	 genuine	 risk	 of	 worsening	 late	 effects.	 However,	 in	 the	 current	 study	 we	
identified	the	possibility	of	a	rebound	response	over	time	regarding	the	microvasculature.	
Though	 a	 general	 trend	 of	 decrease	 in	 vascularity	 was	 evident	 several	 years	 after	
treatment	the	sample	size	used	in	this	study	do	not	allow	us	to	establish	the	exact	effect	
of	time	in	the	microvasculature.	Whether	this	rebound	phenomenon	is	genuine	cannot	be	
fully	determined	 from	this	 study	but	 is	a	 legitimate	possibility.	Angiogenesis	has	been	
 156 
































positively	 and	 negatively	 via	 numerous	 factors	 such	 as	 age,	 medical	 conditions,	
medications	and	localised	disease.	In	the	latter,	specific	to	the	oral	cavity	this	can	range	
from	 periodontitis	 to	 mucositis.	 Additionally,	 the	 role	 of	 chemotherapy	 on	 the	
microvasculature	is	unknown.	Some	forms	of	chemotherapy	are	known	to	cause	vascular	
















According	 to	 all	 CAA	 parameters	 there	 was	 a	 significant	 difference	 between	 the	
microvascular	anatomy	in	the	buccal	and	the	lingual	aspect	of	the	gingival	margin.	The	
reason	for	this	was	not	fully	determined.	Potentially,	it	may	be	related	with	the	technical	






















































































the	 only	 option.	 With	 advances	 in	 RT	 delivery	 and	 accuracies	 in	 retrieving	 doses	 to	











negative	effects	 (R.	E.	Marx,	1983).	 In	contrast,	Delanian	and	colleagues	suggested	 the	
concept	of	RIF	(S	Delanian	&	Lefaix,	2004)	where	a	fibroblastic	expansion	at	the	expense	
of	 other	 cellular	 population	 and	 of	 vascular	 plasticity	 (vascular	 stiffening	 and	 lumen	






are	 well	 known	 parameters	 (Liu	 et	 al.,	 2013)	 affecting	 the	 success	 and	 long-term	
predictability	of	dental	implants.		
	









specimens	 (e.g.	whole	mandibular	 ramus)	which	do	not	necessarily	 reflect	 the	area	of	
ORN	vulnerability	which	is	the	dento-alveolar	segment.	This	is	of	particular	importance	
considering	this	is	where	the	dentition	and	dental	implants	are	placed	and	where	ORN	
most	 commonly	 occurs.	 	 Furthermore,	 assessing	 the	 inferior	 alveolar	 artery	 and	 the	
periosteum	does	 not	 directly	 reflect	 the	 vascularity	 of	 the	 cancellous	 bone.	 Finally,	 in	
several	studies	bone	vascularization	was	assessed	only	 in	 large	vessels	and	not	within	
bone’s	 microvasculature.	 In	 order	 to	 quantify	 radiation-induced	 damage	 to	 the	




cancer	 patients	 and	 the	 subsequent	 vascular	 changes	 in	 the	 dento-alveolar	 region	 of	


























The	 prospective	 patients	 for	 the	 study	 group	 were	 selected	 from	 the	 HNC	 dental	
rehabilitation	clinic.	Patients	requiring	dental	implant	rehabilitation,	having	previously	
(mean:	5.5	years)	had	IMRT	treatment	at	GSTFT		were	included	to	allow	for	accurate	RT	












implant	 procedure	 included	 a	 full	mucoperiosteal	 flap.	 The	 implant	 osteotomies	were	
conducted	under	copious	irrigation	with	sterile	saline.	Initially,	implant	preparation	was	
made	with	a	3.0	mm	bone	trephine	bur	(2.5	mm	inner	diameter)	(Meisinger	Trephine	Kit,	
Meisinger	 Germany,	Manufacturer	 Part	 No:	 7120).	 Post-trephine	 a	 bone	 core	 pick-up	
instrument	allowed	simple	and	atraumatic	specimen	retrieval.	The	aim	was	to	obtain	a	





into	 individual	vials	 filled	with	10%	buffered	 formalin	and	 labelled	to	 their	equivalent	
 162 
dental	site.	Subsequently,	implant	osteotomy	was	completed	in	line	with	the	Astra	Tech	
Implant	 system	 protocol.	 Implants	 placed	 were	 either	 4.0mm	 or	 5.0mm	 in	 width	 or	










































Following	 removal,	 bone	 cores	were	 immediately	 fixed	 in	 10%	 (v/v)	 buffered	 formal	
saline	for	24	hours,	then	decalcified	whole	in	10%	(v/v)	buffered	formic	acid.	Endpoint	









CD31	 (Dako	 M0823,	 Clone	 JC70A.	 using	 Roche	 antibody	 diluent	 251-018	 at	 1:25)	











and	 quality	 of	 staining	 varied	 widely	 within	 our	 sample	 set,	 simple	 threshold-based	
features	 extraction	 algorithms	 (Veschini	 et	 al.,	 2011)	 were	 insufficient	 to	 unbiasedly	
evaluate	all	the	images.	To	overcome	this	limitation,	we	developed	a	novel	ImageJ	macro	
relying	 on	 a	machine	 learning	 core	which	 takes	 advantage	 of	 the	WEKA	 segmentator	
plugin	 (ImageJ)	 (Arganda-Carreras	 et	 al.,	 2017).	 In	 brief,	 firstly	 .tif	 images	 were	 pre-
filtered	 (adjust	 brightness	 contrast,	 unsharp	mask).	 Pre-filtered	 images	 were	 used	 to	
generate	a	training	set	for	the	WEKA	segmentator	plugin	composed	of	a	single	image	stack	
containing	 90	 slices	 (250X250	 px).	 The	 trainer	 stack	 was	 loaded	 into	 the	 WEKA	
segmentator	and	images	were	manually	annotated	to	train	it.	We	generated	two	models,	
the	first	to	distinguish	vessel	(CD31	positive	structures)	and	the	second	to	distinguish	soft	
tissue	 juxtaposed	 to	 bone	 lamellae	 from	 tissue	 or	 background.	We	 applied	 the	WEKA	
segmentator	to	generate	segmentation	maps	for	all	sample	set.	Segmentation	maps	were	
 164 
thresholded	 and	 particle	 analysis	 performed	 to	 generate	 a	 result	 table.	 The	 macro	
returned	a	comma-separated	values	(.csv)	file	containing	number	of	vessels	per	image,	
calibre	of	each	vessel	and	other	geometric	 features	useful	 to	 filter	out	non-meaningful	
results	(e.g.	very	large	structures	representative	of	dilated	vascular	sinuses	rather	than	
micro	 vessels).	 Data	 were	 pre-selected	 in	 Microsoft	 Excel	 to	 filter	 out	 all	 non-












El 2.4- 44.3 Gy
El 2.2- 37.8 GyEl 3.3- 36.3 Gy
El 4.3- 47.1 GyEl 2.2- 40.6 Gy
El 3.3- 36.3 Gy
El 3.3- 28.8 GyEl 4.3- 27.6 GyEl 3.4- 24.3 Gy










































Figure 2: Representative photomicrographs of different samples which received the indicated radiation. Dose
(text inset) and laid out according to the categories used for quantification (rows). Arrow indicate patent vessels,






















Within	 the	 prospective	 group,	 the	 oropharynx	 (n=5/9,	 56%)	 was	 the	 most	 common	




range	 of	 dental	 sites	 extending	 no	 further	 than	 the	 2nd	 premolar	 region	 in	 both	 jaws.	











obliterated	 lumens	 (Figure	 7.3	 arrowheads).	 Finally,	 samples	 which	 received	 high	









with	previously	reported	results,	 indeed,	we	 found	 that	overall,	 the	MVD	of	 irradiated	
patients	was	markedly	reduced	(Figure	7.6A,	653.5	±	326.3	vs	387.7	±	209.4,	p=	0.0034).		
	



































Control	 1	 M	 48	 T2N0	 Retromolar	 L	 N/A	 N/A	 N/A	 Y	 Nil	
2	 F	 50	 N/A	 Mandible	
ameloblastoma	
L	 N/A	 N/A	 N/A	 N	 Nil	
3	 F	 72	 T4N0	 Alveolus	 R	 N/A	 N/A	 N/A	 N	 Nil	
4	 M	 55	 T4N0	 Maxilla	 L	 N/A	 N/A	 N/A	 Y	 Nil	
5	 F	 58	 T4N2	 Alveolus	 Midline	 N/A	 N/A	 N/A	 N	 Nil	
6	 M	 47	 N/A	 Mandible	
ameloblastoma	
Midline	 N/A	 N/A	 N/A	 N	 Nil	
7	 M	 72	 T4N0	 Mandible	 R	 N/A	 N/A	 N/A	 Y	 Nil	
8	 M	 66	 T4N2	 Mandible	 Midline	 N/A	 N/A	 N/A	 Y	 Nil	
9	 M	 59	 T3N0	 Maxilla	 R	 N/A	 N/A	 N/A	 Y	 Nil	
	 	
Prospective	 10	 M	 53	 T1N1	 NP	 N/A	 RT	 54	 N/A	 N	 Nil	
11	 M	 55	 T2N2	 OP	 R	 CRT	 65	 Cisplatin	 Y	 Nil	
12	 M	 46	 T3N2	 OP	 R	 CRT	 65	 Carboplatin	 N	 Nil	
13	 F	 66	 T4N2	 HP	 L	 CRT	 65	 Carboplatin	 Y	 Nil	
14	 M	 58	 T4N1	 HP	 N/A	 RT	 60	 N/A	 Y	 Hypercholesterolemia	
15	 M	 72	 T3N2	 OP	 R	 CRT	 65	 Cisplatin	 X	 Nil	
16	 F	 65	 T4N1	 OP	 L	 CRT	 65	 Carboplatin	
&5FU	
N	 Nil	
17	 M	 61	 T1N2	 OP	 R	 CRT	 65	 Cisplatin	 Y	 Emphysema	
Hypertension	































































































































































































































































































Dmax	 43.9	(10.6)	 43.7	 61.8-31.2	
Dmean	 38.4	(10.8)	 37.8	 59.6-24.3	














































Fig 3 A) MVD of irradiated vs non-irradiated sites. Black line represent the mean of the group B) schematic 

















































Fig 4 A) Linear regression analysis of MVD against RT dose. Black line is the best extrapolated fitting line and the 
dashed lines represent the 95% confidence bands. B) Violin plot of the five categories, red lines represent the median 
for the group (50th percentile), dashed black lines are the 25th and 75th percentiles. C) Distribution (number of 
values) of micro vessels across the five RT categories (colours) and 3 calibre categories smalles , medium and 





with	 a	 substantial	 finding	 that	 a	 significant	 threshold	 is	 30Gy.	Historically,	 the	 threshold	was	
considered	40Gy	which	led	to	impairment	of	bone	regeneration	capacity	(Schoen	et	al.,	2007).	
Progression	 and	 failure	 of	 this	 process	 commencing	 at	 40Gy	 risked	 the	 development	 of	 ORN	
(Cooper,	2003).	Identification	of	this	lower	threshold	of	30Gy	is	a	clinical	concern.	Patients	with	
tumours	of	the	oropharynx,	nasopharynx	and	hypopharynx	all	routinely	receive	doses	in	excess	
of	 this	 to	 the	 jaws	 (Bak	 et	 al.,	 2016).	 This	 new	 lower	 threshold	 should	 be	 no	 surprise	when	
considering	surrounding	structures	such	as	enamel	(de	Barros	da	Cunha	et	al.,	2017),	dental	pulp	




completed	 their	 RT	 over	 12	months	 prior.	 This	 finding	 highlights	 the	 sustained	 and	 residual	























based	 on	 site	 specific	RT	doses	 rather	 than	using	 total	 clinical	 dose.	 The	use	 of	 specific	 dose	
provides	a	more	accurate	and	true	representation	of	the	status	of	irradiated	bone.	In	contrast,	the	
use	of	ORN	resections	to	assess	vascularity	 is	 likely	to	 identify	profound	 lack	of	blood	supply,	
hence,	leading	to	bone	death.	The	study	by	Dekker	et	al	comparing	irradiated	mandibles	versus	
controls	using	CD34	antibody	stain	to	detect	endothelial	cells	identified	similar	findings	(Dekker	















al.,	 2016;	 Hansen	 et	 al.,	 2012;	 Parahyba	 et	 al.,	 2016;	 Rosenthal	 et	 al.,	 2008)	 (Chapter	 5)	 .	 In	
addition,	 HPV	 positive	 OPC	 have	 significantly	 improved	 overall-	 and	 disease-free	 survival	
compared	 to	 site-	 and	 stage-matched	HPV-negative	 tumours	 (Ang	 et	 al.,	 2010;	 Pytynia	 et	 al.,	
2014).	In	addition,	one	should	consider	the	remarkable	increase	in	the	incidence	of	OPC	in	the	






























Secondly,	 there	 is	 a	 clinical	 bias	 based	 on	 patient	 selection.	 Implant	 placement	 within	 our	
































































and	 HPV	 negative	 tumours.	 The	 former	 has	 significantly	 more	 teeth	 than	 the	 latter.	 Once	





have	more	 teeth	 than	other	HNC	patients	 it’s	 the	 subsequent	post-RT	effect	 to	 them	which	 is	
concerning.	In	the	HPV	positive	group,	a	difference	of	9	teeth	was	identified	at	the	pre-RT	phase	























tumour	 side	 receive	 near	 total	 amount.	 In	 the	 larger	 tumour	 group	 the	 same	 hold	 true	 for	
contralateral	side.	Currently	this	applies	to	a	large	population	group	within	OPC	considering	that	
HPV	 positive	 disease	 is	 an	 indolent	 disease	 often	 presenting	 as	 large	 painless	 neck	 lump.	
Currently	 this	 is	 considered	 advance	 disease	 and	 RT	 is	 delivered	 to	 the	 neck	 bilaterally.	
Subsequently	the	jaws	become	incorporated	within	the	field	and	with	a	large	area	of	the	dento-













































managed	 identically	 to	 their	HPV	negative	 colleagues	by	both	 the	oncology	 and	dental	 sector	
which	in	part	may	explain	the	skewed	leniency	for	why	this	group	suffers	from	a	heavier	burden	
of	ORN.	Though	strategic	efforts	have	been	employed	to	avoid	the	occurrence	of	ORN	these	have	






era.	 This	 complex	 dental	 presentation	 invites	 its	 own	 challenges	 which	 require	 long	 term	
maintenance	however	the	added	threat	of	a	changing	oral	environment	post-RT	makes	each	tooth	
a	vulnerable	 target	 for	 radiation	caries	and	subsequent	extraction.	With	 this	group	exhibiting	





slowed,	 delayed	 or	 even	 eliminated	 the	 risk	 of	 ORN	 is	 likely	 to	 fall	 accordingly.	 Medical	
management	 in	 reversing	 radiation	 damage	 has	 seen	 some	 recent	 success.	 Additionally,	



























bone	 core	 study	has	provided	 invaluable	 insight	 regarding	 the	RT	 changes	 in	hard	 tissue	but	
requires	further	assessment	including	investigation	of	cell	cultures	and	having	a	larger	cohort	to	























































































	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
							 T1N0			L	 41.2	 38.6	 36.4	 31.6	 24.4	 20.7	 25.5	 28.1	 29	 31.4	 32.9	 36.8	 43.1	 51.1	 59.3	 63.4	
	 T1N0		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
	 T1N1			L	 32.7	 35	 36.4	 35.7	 33.6	 27.7	 31	 33	 32.9	 34.9	 37.9	 44.3	 52	 59.3	 61.2	 63.6		
T1N1		R	 64	 58.2	 48.9	 37.5	 36.9	 28.7	 29.3	 29.7	 26.3	 18.8	 15.4	 18.4	 23.6	 28.8	 33.2	 37.4		
T1N2			L	 49.1	 47.4	 44.9	 42.1	 38.9	 32.5	 30.8	 30.2	 32.1	 33.8	 35.4	 38.3	 42.6	 48.8	 56.9	 61.5		
T1N2		R	 56.9	 52.5	 46.9	 46	 38.2	 35.9	 34.2	 32.9	 32.5	 33.6	 36	 40.7	 45.1	 49.6	 51.5	 52.6		
T1N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T1N3		R	 64.4	 57.6	 48.5	 44	 30.9	 21.2	 19.2	 17.8	 22.2	 25.5	 25.8	 27.3	 29.8	 30.8	 33.2	 44.2	
N	=	31	 	 	
	
T1N3		R	 63.6	 63.4	 57.7	 52	 45	 41.2	 40.6	 40.9	
	
40.4	 40.9	 39.6	 39.1	 39.6	 42.1	 47.3	 44		
T1N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T1N2		R	 62.1	 59.4	 54.1	 46.6	 40.7	 37.5	 35.2	 33.7	 33.4	 33.4	 37.2	 42.7	 46.9	 49	 49.7	 49.9		
T1N2			L	 47.9	 48.9	 49.6	 47.8	 43	 38.2	 35.7	 35.2	 35.3	 36.1	 38.5	 43.4	 51.6	 58.3	 61.8	 63		
T1N1		R	 62.8	 60.6	 51.6	 42.5	 45.7	 38.4	 33.7	 34.4	 37.7	 34.8	 24	 24.8	 28.9	 31.9	 32.9	 34.9		
T1N1			L	 23.9	 26.9	 34.1	 36	 36.7	 38.3	 40.9	 40.6	 41	 42.5	 45.7	 50.7	 57.5	 62.8	 64.8	 64		
T1N0		R	 64.6	 61.7	 49.4	 34.9	 30.8	 32	 30.7	 27.8	 21.4	 20.7	 19.9	 18.6	 18.9	 23.6	 25.5	 26.8		
T1N0			L	 29.8	 32.8	 35.7	 33.9	 31.3	 29.3	 30.6	 29.6	 28.4	 29.5	 31.7	 34.1	 40	 51.4	 61	 61.7		








	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	 T2N0			L	 45.8	 41.9	 38.6	 32.4	 27.4	 25	 24.8	 24	 25.4	 27.9	 28.9	 33.6	 39.4	 47.6	 56.9	 64	
	 T2N0		R	 59.3	 57.9	 50.2	 41.3	 37.4	 35.3	 32.6	 31.9	 31.1	 26.7	 23	 25.6	 27.6	 27.8	 29.4	 35.6	
	 T2N1			L	 59.8	 55.6	 57.4	 55	 47.9	 41.2	 37.6	 34.9	 35.3	 36.2	 38.4	 39.7	 43.2	 49.5	 59.7	 64.8		
T2N1		R	 61.6	 52.7	 43.5	 40.4	 36.6	 33.5	 30.5	 28.9	 30	 32	 34.1	 40.5	 46.9	 52.5	 57.1	 60.4		
T2N2			L	 53.9	 50.5	 48.7	 45.4	 41.4	 37.1	 35.6	 35	 35.7	 37.7	 39.5	 42.2	 45.6	 50.5	 58	 63.4		
T2N2		R	 61.6	 56.8	 51.3	 46.6	 42.2	 38.6	 36.5	 34.2	 33.3	 33.7	 35.3	 38.7	 42.6	 46.4	 48.9	 52.6		
T2N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T2N3		R	 64.3	 60.4	 56.1	 50.3	 46.7	 44.6	 42.2	 40.2	 39.5	 43.1	 47.7	 53.4	 55.4	 55.7	 57.5	 61.4	
N	=	62	 	 	
	
T2N3		R	 61.7	 60.8	 58.6	 52.5	 45.7	 40	 36.8	 36.1	
	
36.7	 39.3	 33.8	 51.9	 57	 56.8	 55.9	 55.7		
T2N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T2N2		R	 63.1	 61.7	 57.4	 51.3	 47	 43.3	 40.1	 38.6	 38.1	 38.4	 40.1	 43.8	 47.9	 50.2	 51	 51.5		
T2N2			L	 51.2	 49.9	 49.4	 47.8	 44.1	 40.4	 38.8	 38.4	 38.8	 39.5	 41.7	 46.7	 52.1	 57.4	 61.6	 63.1		
T2N1		R	 64.9	 62.7	 55.9	 47.7	 39	 33.4	 31	 30.6	 32.7	 34.9	 38.3	 45.2	 49.8	 53.9	 56.6	 59.1		
T2N1			L	 49	 51.5	 54.5	 54.5	 48.8	 41.6	 38.1	 37.9	 39.1	 39.7	 40.6	 43.7	 48.4	 53.3	 58.9	 62.5		
T2N0		R	 61.3	 59	 52.1	 43.7	 39.6	 37.7	 36.7	 37	 37.2	 36.8	 35.6	 35.7	 36.8	 36.5	 36.1	 36.7		
T2N0			L	 40.6	 42.4	 42.3	 39.1	 36.5	 34.9	 33.8	 32.1	 32.4	 34.4	 37.3	 42.7	 48.5	 56.4	 62.2	 63.5		







		 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
		 T3N0			L	 50.5	 46.6	 44.6	 39.3	 41.2	 37.5	 34.9	 34.6	 36.4	 36.3	 36.7	 41.6	 40.4	 48.5	 54.7	 61.2	
		 T3N0		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
		 T3N1			L	 60.8	 52.9	 51	 45.1	 37.6	 28.5	 22.9	 19.5	 19.2	 20.1	 22.7	 28.9	 38	 49.3	 54.7	 61.6	
		 T3N1		R	 64.2	 64.4	 63.5	 63.4	 60.5	 55	 51.9	 48.9	 47	 47.9	 50.1	 54.9	 56.1	 55.9	 52.7	 55.9	
		 T3N2			L	 52.6	 48.5	 46.3	 42.9	 38.1	 34.1	 32.8	 32.3	 32.6	 34.1	 35.4	 38.5	 43	 50.7	 56.5	 60.9	
		 T3N2		R	 62	 59.2	 54.2	 50.5	 46.6	 42	 39.1	 36.8	 35.8	 39.3	 43.9	 47.8	 50.3	 50.8	 51.6	 54.6	
		 T3N3			L	 59.5	 56.1	 52.6	 46.4	 38.3	 31.7	 24.4	 21	 19.1	 19.9	 23.2	 28.4	 38.6	 49.6	 59.8	 63.8	
		 T3N3		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
N	=	33	 	 	
		 T3N3		R	 64.5	 58.4	 52.2	 49.5	 47.4	 46	 41	 35.7	
	
35.6	 36.9	 37.8	 39.2	 42.5	 46.1	 48.3	 50.8	
		 T3N3			L	 60.7	 61.6	 58	 49	 41.4	 33	 28.4	 28	 28.7	 30.3	 32.9	 37.9	 43.3	 52.8	 59.8	 61.3	
		 T3N2		R	 63.4	 62.9	 61	 56.6	 52	 47.2	 42.7	 40.3	 39.7	 40.3	 42.6	 47.5	 51.2	 52.4	 50.9	 49.4	
		 T3N2			L	 52.2	 50.8	 48.7	 46.3	 43	 39.2	 37	 36.1	 36.9	 38.2	 40.2	 44.6	 49.6	 56	 60.8	 62.3	
		 T3N1		R	 63.5	 64.1	 65	 64.7	 62.2	 58.7	 57.5	 58	 58.6	 59.5	 60.2	 61.5	 60.7	 60	 54.5	 54	
		 T3N1			L	 55.9	 58	 55	 52.2	 48.4	 40	 30.4	 26.5	 23.6	 22.8	 24.9	 31.5	 47.4	 58.5	 60.8	 59.7	
		 T3N0		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
		 T3N0			L	 50.1	 48.3	 47.4	 47.9	 46.5	 42.7	 39.1	 37	 36.6	 37.4	 39.7	 46.8	 55.8	 61.5	 62.5	 62.8	








	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	 T4N0			L	 56.1	 53.1	 50.1	 44.5	 39.6	 33.7	 31.1	 29.9	 31.1	 33.5	 35.7	 40	 45.5	 51.2	 58.7	 64.8	
	 T4N0		R	 65.5	 63.9	 59.8	 52.8	 45.4	 39	 28.9	 25.4	 24.7	 28	 30.2	 32.9	 37.4	 42.6	 47.2	 51.1	
	 T4N1			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T4N1		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T4N2			L	 53.2	 49.6	 46.8	 43.4	 40	 36.4	 35	 33.4	 35.7	 38.6	 40.2	 42.8	 46	 51.1	 56.6	 60		
T4N2		R	 63.1	 55.7	 49.8	 44.9	 40.6	 36.2	 34.5	 34.3	 34.2	 33.8	 33.7	 37	 40	 43.5	 46.7	 52.1		
T4N3			L	 58.8	 55.9	 49.7	 46.8	 40.5	 37.9	 36.1	 35.5	 39.4	 42.6	 45.4	 48.8	 59.2	 54.2	 60.9	 65.5		
T4N3		R	 63.3	 62.3	 61.3	 59.1	 -	 53.6	 49.2	 46.1	 43.7	 42.8	 44	 -	 51.7	 56.8	 57.9	 60.1	
N	=	34	 	 	
	
T4N3		R	 63.9	 63.9	 63.7	 61.1	 -	 54.5	 49.9	 45.6	
	
43.8	 44.9	 49.4	 -	 52.1	 50.1	 48.4	 43.6		
T4N3			L	 59.5	 59.3	 58.2	 56.2	 51.9	 47	 44.1	 42.9	 42.8	 43.4	 45	 50.1	 56.5	 60.8	 64.2	 65.4		
T4N2		R	 65.4	 65.7	 62.6	 57.2	 52.1	 48.9	 46	 44.5	 43.5	 43.8	 45.4	 47.8	 51.5	 53.9	 57.6	 59		
T4N2			L	 55.9	 54.6	 53	 51.6	 48.1	 45.9	 44	 43.4	 43.4	 44.4	 46.8	 50.9	 56	 58.8	 62.1	 63.2		
T4N1		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T4N1			L	 52.6	 54.2	 60	 59.8	 59.3	 57.8	 55	 52.5	 50.1	 50.8	 53.9	 58.8	 62.2	 63.9	 64	 62.3		
T4N0		R	 63.5	 63	 59	 46.7	 41.4	 39.7	 35.6	 28.9	 25	 23.3	 23.3	 25.1	 28.9	 30	 31.9	 36.1		
T4N0			L	 53.4	 52.8	 51.2	 49.5	 46.2	 42	 37.9	 35.5	 34.1	 34.1	 35.8	 40.5	 47.2	 55.3	 60.8	 63.2		








	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	 T1N0			L	 41.2	 38.6	 36.4	 31.6	 24.4	 20.7	 25.5	 28.1	 29	 31.4	 32.9	 36.8	 43.1	 51.1	 59.3	 63.4	
	 T1N0		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
	 T2N0			L	 45.8	 41.9	 38.6	 32.4	 27.4	 25	 24.8	 24	 25.4	 27.9	 28.9	 33.6	 39.4	 47.6	 56.9	 64		
T2N0		R	 59.3	 57.9	 50.2	 41.3	 37.4	 35.3	 32.6	 31.9	 31.1	 26.7	 23	 25.6	 27.6	 27.8	 29.4	 35.6		
T3N0			L	 50.5	 46.6	 44.6	 39.3	 41.2	 37.5	 34.9	 34.6	 36.4	 36.3	 36.7	 41.6	 40.4	 48.5	 54.7	 61.2		
T3N0		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T4N0			L	 56.1	 53.1	 50.1	 44.5	 39.6	 33.7	 31.1	 29.9	 31.1	 33.5	 35.7	 40	 45.5	 51.2	 58.7	 64.8		
T4N0		R	 65.5	 63.9	 59.8	 52.8	 45.4	 39	 28.9	 25.4	 24.7	 28	 30.2	 32.9	 37.4	 42.6	 47.2	 51.1	
N	=	30	 	 	
	
T4N0		R	 63.5	 63	 59	 46.7	 41.4	 39.7	 35.6	 28.9	
	
25	 23.3	 23.3	 25.1	 28.9	 30	 31.9	 36.1		
T4N0			L	 53.4	 52.8	 51.2	 49.5	 46.2	 42	 37.9	 35.5	 34.1	 34.1	 35.8	 40.5	 47.2	 55.3	 60.8	 63.2		
T3N0		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T3N0			L	 50.1	 48.3	 47.4	 47.9	 46.5	 42.7	 39.1	 37	 36.6	 37.4	 39.7	 46.8	 55.8	 61.5	 62.5	 62.8		
T2N0		R	 61.3	 59	 52.1	 43.7	 39.6	 37.7	 36.7	 37	 37.2	 36.8	 35.6	 35.7	 36.8	 36.5	 36.1	 36.7		
T2N0			L	 40.6	 42.4	 42.3	 39.1	 36.5	 34.9	 33.8	 32.1	 32.4	 34.4	 37.3	 42.7	 48.5	 56.4	 62.2	 63.5		
T1N0		R	 64.6	 61.7	 49.4	 34.9	 30.8	 32	 30.7	 27.8	 21.4	 20.7	 19.9	 18.6	 18.9	 23.6	 25.5	 26.8		
T1N0			L	 29.8	 32.8	 35.7	 33.9	 31.3	 29.3	 30.6	 29.6	 28.4	 29.5	 31.7	 34.1	 40	 51.4	 61	 61.7		








	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	 T1N1			L	 32.7	 35	 36.4	 35.7	 33.6	 27.7	 31	 33	 32.9	 34.9	 37.9	 44.3	 52	 59.3	 61.2	 63.6	
	 T1N1		R	 64	 58.2	 48.9	 37.5	 36.9	 28.7	 29.3	 29.7	 26.3	 18.8	 15.4	 18.4	 23.6	 28.8	 33.2	 37.4	
	 T2N1			L	 59.8	 55.6	 57.4	 55	 47.9	 41.2	 37.6	 34.9	 35.3	 36.2	 38.4	 39.7	 43.2	 49.5	 59.7	 64.8		
T2N1		R	 61.6	 52.7	 43.5	 40.4	 36.6	 33.5	 30.5	 28.9	 30	 32	 34.1	 40.5	 46.9	 52.5	 57.1	 60.4		
T3N1			L	 60.8	 52.9	 51	 45.1	 37.6	 28.5	 22.9	 19.5	 19.2	 20.1	 22.7	 28.9	 38	 49.3	 54.7	 61.6		
T3N1		R	 64.2	 64.4	 63.5	 63.4	 60.5	 55	 51.9	 48.9	 47	 47.9	 50.1	 54.9	 56.1	 55.9	 52.7	 55.9		
T4N1			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T4N1		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
N	=	14	 	 	
	
T4N1		R	 -	 -	 -	 -	 -	 -	 -	 -	
	
-	 -	 -	 -	 -	 -	 -	 -		
T4N1			L	 52.6	 54.2	 60	 59.8	 59.3	 57.8	 55	 52.5	 50.1	 50.8	 53.9	 58.8	 62.2	 63.9	 64	 62.3		
T3N1		R	 63.5	 64.1	 65	 64.7	 62.2	 58.7	 57.5	 58	 58.6	 59.5	 60.2	 61.5	 60.7	 60	 54.5	 54		
T3N1			L	 55.9	 58	 55	 52.2	 48.4	 40	 30.4	 26.5	 23.6	 22.8	 24.9	 31.5	 47.4	 58.5	 60.8	 59.7		
T2N1		R	 64.9	 62.7	 55.9	 47.7	 39	 33.4	 31	 30.6	 32.7	 34.9	 38.3	 45.2	 49.8	 53.9	 56.6	 59.1		
T2N1			L	 49	 51.5	 54.5	 54.5	 48.8	 41.6	 38.1	 37.9	 39.1	 39.7	 40.6	 43.7	 48.4	 53.3	 58.9	 62.5		
T1N1		R	 62.8	 60.6	 51.6	 42.5	 45.7	 38.4	 33.7	 34.4	 37.7	 34.8	 24	 24.8	 28.9	 31.9	 32.9	 34.9		
T1N1			L	 23.9	 26.9	 34.1	 36	 36.7	 38.3	 40.9	 40.6	 41	 42.5	 45.7	 50.7	 57.5	 62.8	 64.8	 64		








	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	 T1N2			L	 49.1	 47.4	 44.9	 42.1	 38.9	 32.5	 30.8	 30.2	 32.1	 33.8	 35.4	 38.3	 42.6	 48.8	 56.9	 61.5	
	 T1N2		R	 56.9	 52.5	 46.9	 46	 38.2	 35.9	 34.2	 32.9	 32.5	 33.6	 36	 40.7	 45.1	 49.6	 51.5	 52.6	
	 T2N2			L	 53.9	 50.5	 48.7	 45.4	 41.4	 37.1	 35.6	 35	 35.7	 37.7	 39.5	 42.2	 45.6	 50.5	 58	 63.4		
T2N2		R	 61.6	 56.8	 51.3	 46.6	 42.2	 38.6	 36.5	 34.2	 33.3	 33.7	 35.3	 38.7	 42.6	 46.4	 48.9	 52.6		
T3N2			L	 52.6	 48.5	 46.3	 42.9	 38.1	 34.1	 32.8	 32.3	 32.6	 34.1	 35.4	 38.5	 43	 50.7	 56.5	 60.9		
T3N2		R	 62	 59.2	 54.2	 50.5	 46.6	 42	 39.1	 36.8	 35.8	 39.3	 43.9	 47.8	 50.3	 50.8	 51.6	 54.6		
T4N2			L	 53.2	 49.6	 46.8	 43.4	 40	 36.4	 35	 33.4	 35.7	 38.6	 40.2	 42.8	 46	 51.1	 56.6	 60		
T4N2		R	 63.1	 55.7	 49.8	 44.9	 40.6	 36.2	 34.5	 34.3	 34.2	 33.8	 33.7	 37	 40	 43.5	 46.7	 52.1	
N	=	107	 	 	
	
T4N2		R	 65.4	 65.7	 62.6	 57.2	 52.1	 48.9	 46	 44.5	
	
43.5	 43.8	 45.4	 47.8	 51.5	 53.9	 57.6	 59		
T4N2			L	 55.9	 54.6	 53	 51.6	 48.1	 45.9	 44	 43.4	 43.4	 44.4	 46.8	 50.9	 56	 58.8	 62.1	 63.2		
T3N2		R	 63.4	 62.9	 61	 56.6	 52	 47.2	 42.7	 40.3	 39.7	 40.3	 42.6	 47.5	 51.2	 52.4	 50.9	 49.4		
T3N2			L	 52.2	 50.8	 48.7	 46.3	 43	 39.2	 37	 36.1	 36.9	 38.2	 40.2	 44.6	 49.6	 56	 60.8	 62.3		
T2N2		R	 63.1	 61.7	 57.4	 51.3	 47	 43.3	 40.1	 38.6	 38.1	 38.4	 40.1	 43.8	 47.9	 50.2	 51	 51.5		
T2N2			L	 51.2	 49.9	 49.4	 47.8	 44.1	 40.4	 38.8	 38.4	 38.8	 39.5	 41.7	 46.7	 52.1	 57.4	 61.6	 63.1		
T1N2		R	 62.1	 59.4	 54.1	 46.6	 40.7	 37.5	 35.2	 33.7	 33.4	 33.4	 37.2	 42.7	 46.9	 49	 49.7	 49.9		
T1N2			L	 47.9	 48.9	 49.6	 47.8	 43	 38.2	 35.7	 35.2	 35.3	 36.1	 38.5	 43.4	 51.6	 58.3	 61.8	 63		








	 	 UR8	 UR7	 UR6	 UR5	 UR4	 UR3	 UR2	 UR1	
	
UL1	 UL2	 UL3	 UL4	 UL5	 UL6	 UL7	 UL8	
	 T1N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
	 T1N3		R	 64.4	 57.6	 48.5	 44	 30.9	 21.2	 19.2	 17.8	 22.2	 25.5	 25.8	 27.3	 29.8	 30.8	 33.2	 44.2	
	 T2N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T2N3		R	 64.3	 60.4	 56.1	 50.3	 46.7	 44.6	 42.2	 40.2	 39.5	 43.1	 47.7	 53.4	 55.4	 55.7	 57.5	 61.4		
T3N3			L	 59.5	 56.1	 52.6	 46.4	 38.3	 31.7	 24.4	 21	 19.1	 19.9	 23.2	 28.4	 38.6	 49.6	 59.8	 63.8		
T3N3		R	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T4N3			L	 58.8	 55.9	 49.7	 46.8	 40.5	 37.9	 36.1	 35.5	 39.4	 42.6	 45.4	 48.8	 59.2	 54.2	 60.9	 65.5		
T4N3		R	 63.3	 62.3	 61.3	 59.1	 -	 53.6	 49.2	 46.1	 43.7	 42.8	 44	 -	 51.7	 56.8	 57.9	 60.1	
N	=	9	 	 	
	
T4N3		R	 63.9	 63.9	 63.7	 61.1	 -	 54.5	 49.9	 45.6	
	
43.8	 44.9	 49.4	 -	 52.1	 50.1	 48.4	 43.6		
T4N3			L	 59.5	 59.3	 58.2	 56.2	 51.9	 47	 44.1	 42.9	 42.8	 43.4	 45	 50.1	 56.5	 60.8	 64.2	 65.4		
T3N3		R	 64.5	 58.4	 52.2	 49.5	 47.4	 46	 41	 35.7	 35.6	 36.9	 37.8	 39.2	 42.5	 46.1	 48.3	 50.8		
T3N3			L	 60.7	 61.6	 58	 49	 41.4	 33	 28.4	 28	 28.7	 30.3	 32.9	 37.9	 43.3	 52.8	 59.8	 61.3		
T2N3		R	 61.7	 60.8	 58.6	 52.5	 45.7	 40	 36.8	 36.1	 36.7	 39.3	 33.8	 51.9	 57	 56.8	 55.9	 55.7		
T2N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		
T1N3		R	 63.6	 63.4	 57.7	 52	 45	 41.2	 40.6	 40.9	 40.4	 40.9	 39.6	 39.1	 39.6	 42.1	 47.3	 44		
T1N3			L	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -		





















	 BoT	 Tonsil	 Patel		
Mandible		-	Anteriors	 33.6	 34.9	 41.5	–	37.8	
Mandible	-	Premolars	 40.4	 42.5	 49.0	–	44.3	
Mandible	–	1st	Molar	 46.7	 52.3	 53.1	–	52.9	
Mandible		-	2nd	Molar	 51.0	 48.3	 55.6	–	55.5	
Mandible	–	3rd	Molar	 60.3	 50.0	 56.5	
	
Maxilla		-	Anteriors	 27.9	 38.9	 36.3	–	33.0	
Maxilla	-	Premolars	 35.7	 41.8	 44.8	–	39.8	
Maxilla	–	1st	Molar	 41.4	 48.8	 48.6	–	48.4	
Maxilla		-	2nd	Molar	 43.8	 47.6	 53.2	–	52.4	











	 T1-2/N2-3	 Patel	 T3-4/N2-3	 Patel	 T1-4N0	 Patel	























	 Parahyba	(Dmax)	 Patel	(Dmax)	 Parahyba	(Dmean)	 Patel	(Dmean)	
Upper	right	quadrant	 35.7	 62.7	–	46.8	 27.4	 56.4	–	40.0	
Upper	anteriors	 26.1	 42.8	–	42.2	 16.6	 36.3	–	36.1	
Upper	left	quadrant	 35.2	 63.6	–	46.4	 26.4	 57.5	–	39.8	
	
Lower	left	quadrant	 44.3	 63.1	–	50.9	 35.3	 56.5	–	44.3	
Lower	anteriors	 35.5	 47.8	–	46.5	 25.4	 41.5	–	40.2	
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18 November 2016 
 
 Prof Lucy Di Silvio 
Dental Research, Fl 17, Tower Wing 




Dear Prof Di Silvio  
 
Study title: Evaluation of radiation-induced jaw tissue damage to 
predict success of dental implant rehabilitation 
REC reference: 16/LO/1797 
IRAS project ID: 194559 
 
Thank you for your letter, responding to the Committee’s request for further information on the 
above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by Chair in 
consultation with Ms Chadwick, Dr Kabir & Dr Stari.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require 
further information, or wish to make a request to postpone publication, please contact the 
REC Manager, Patrick Walsh, nrescommittee.london-dulwich@nhs.net. 
 
Confirmation of ethical opinion 
 
Please note:  This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at NHS 
sites in England until you 
receive HRA Approval  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given permission 
for the research to proceed (except where explicitly specified otherwise).  
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 




The final list of documents reviewed and approved by the Committee is as follows: 
Document   Version   Date   
Covering letter on headed paper    06 September 2016  
Covering letter on headed paper [Response to EC]    04 November 2016  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
  29 June 2016  
GP/consultant information sheets or letters [on gstt headed paper]  1.0  27 October 2016  
IRAS Application Form [IRAS_Form_10112016]    10 November 2016  
Letter from funder    05 May 2016  
Letters of invitation to participant  1.0  07 July 2016  
Other [GDP letter on gstt headed paper]  1.1  27 October 2016  
Participant consent form  1.2  27 October 2016  
Participant information sheet (PIS)  1.2  27 October 2016  
Research protocol or project proposal  1.0  07 July 2016  
Summary CV for Chief Investigator (CI) [Di Silvio]      
Summary CV for student [Patel]      
Summary CV for supervisor (student research) [Thavaraj]      
Summary, synopsis or diagram (flowchart) of protocol in non 
technical language  
1.0  21 July 2016  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 





The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 




We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
 
 
16/LO/1797                          Please quote this number on all correspondence 
 









Enclosures:  “After ethical review – guidance for 
   researchers”  
 
Copy to:  Keith Brennan 
 Jennifer  Boston, Guy's & St Thomas' Foundation NHS Trust 
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Dear Mr Vinod Patel 
 
Study title: Dental status, radiotherapy doses and subsequent 
implications in head and neck cancer patients - A 
retrospective cohort study 
REC reference: 19/EE/0224 
Protocol number: 1.0 
IRAS project ID: 264999 
 
The Proportionate Review Sub-committee of the East of England - Cambridge East Research 




On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting documentation, 
subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS 
management permission (in Scotland) should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements. Each NHS organisation 
Please note:  This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at 
NHS sites in England until 
you receive HRA Approval  
 
must confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for 
research is available in the Integrated Research Application System. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
 
It is a condition of the REC favourable opinion that all clinical trials are registered on a publicly 
accessible database. For this purpose, clinical trials are defined as the first four project 
categories in IRAS project filter question 2. For clinical trials of investigational medicinal 
products (CTIMPs), other than adult phase I trials, registration is a legal requirement. 
 
Registration should take place as early as possible and within six weeks of recruiting the first 
research participant at the latest. Failure to register is a breach of these approval conditions, 
unless a deferral has been agreed by or on behalf of the Research Ethics Committee ( see here 




As set out in the UK Policy Framework, research sponsors are responsible for making 
information about research publicly available before it starts e.g. by registering the research 




You should notify the REC of the registration details.  We routinely audit applications for 
compliance with these conditions.  
 
Publication of Your Research Summary 
 
We will publish your research summary for the above study on the research summaries section 
of our website, together with your contact details, no earlier than three months from the date of 
this favourable opinion letter.  Should you wish to provide a substitute contact point, make a 




It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
After ethical review: Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study, including early termination of the study 
• Final report 
 




Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 




The documents reviewed and approved were: 
 
Document   Version   Date   
IRAS Application Form [IRAS_Form_05062019]    05 June 2019  
IRAS Application Form XML file [IRAS_Form_05062019]    05 June 2019  
IRAS Checklist XML [Checklist_05062019]    05 June 2019  
Research protocol or project proposal [Research Protocol]  V1.0  01 May 2019  
Summary CV for Chief Investigator (CI) [CI CV]    06 April 2019  
 
Membership of the Proportionate Review Sub-Committee 
 
The members of the Sub-Committee who took part in the review are listed on the attached 
sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 




The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 




We are pleased to welcome researchers and research staff to our HRA Learning Events and 
online learning opportunities– see details at: 
https://www.hra.nhs.uk/planning-and-improving-research/learning/  
 
With the Committee’s best wishes for the success of this project. 
 












Enclosures: List of names and professions of members who took part in the review  
 
“After ethical review – guidance for researchers” [SL-AR2] 
 
Copy to: Elizabeth Brunna, GSTT 
 
Lead Nation  
England: HRA.Approval@nhs.net 
 
East of England - Cambridge East Research Ethics Committee 
 
Attendance at PRS Sub-Committee of the REC meeting on 24 June 2019 
 
  
Committee Members:  
 
Name   Profession   Present    Notes   
Mr Edward Gibbes  Freelance journalist  Yes     
Mrs  Victoria Hollamby  Assistant Research 
Governance Advisor  
Yes     
Dr  Derek Prater  Pharmacist  Yes     
  
Also in attendance:  
 
Name   Position (or reason for attending)   
Mr Tad Jones  Approvals Officer  
 
 
